Prevalence and Risk Factors for Relapse in Pulmonary Sarcoidosis: The First Systematic Review, Meta-analysis, and Future Directions

Zia Hashim[1], Naresh Kumar Tripathy[2], Alok Nath[1], Mansi Gupta[1], Ajmal Khan[1], Ajit Kumar[1], Anup Kumar[3]

[1]Department of Pulmonary Medicine; [2]Department of Hematology, [3]Department of Biostatistics and Health Informatics; Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

Corresponding[1]

ABSTRACT

Background and Aim: Relapses are known to adversely affect the prognosis of patients with pulmonary sarcoidosis (PS). However, a systematic review or meta-analysis on the subject is not yet available in the literature.

Research question: What are the global prevalence and underlying risk factors for relapse in PS patients?
patients?

Methods: We systematically searched PubMed, Google Scholar, Scopus, and Embase for eligible PS studies published until 31 January 2025. Eligible studies were peer-reviewed, English-language articles reporting relapse and risk factors in PS patients. Prevalence and risk factors were analysed via proportions and log odds ratios (LORs) with 95% confidence intervals (CIs). Quality was assessed via the Hoy et al. tool for prevalence studies.

Results: Fifty studies with 5978 patients were included; 3646 patients were followed up for relapse analysis. Heterogeneity was significant (I^2=94%). The pooled relapse incidence was 0.40 (95% CI: 0.34–0.46). The estimates were robust in the sensitivity analyses (0.35--0.41). The prevalence was lower in prospective studies (0.32, 95% CI: 0.26--0.38) than in retrospective studies (0.44, 95% CI: 0.36--0.54; meta-regression p=0.02). Relapse risk was greater in black patients (LOR 0.91, 95% CI: 0.44–1.37; p<0.001), those with stage II–III disease (0.55, 95% CI: 0.07–1.03; p=0.02), and those with stage IV disease (1.04, 95% CI: 0.25–1.83; p=0.01) but was comparable for age, sex, treatment type, and PS type (isolated or systemic).

Conclusion: The pooled prevalence of PS relapse was 40%, but it was lower in prospective studies. A black race and higher-grade radiographic stages were the underlying risk factors for disease relapse.

KEYWORDS: pulmonary sarcoidosis, relapse, prevalence, risk factors, meta-analysis, ethnicity

[1] Prof. Alok Nath

Take-Home Message

Research Question: What is the global occurrence and etiology of relapse among patients with pulmonary sarcoidosis illness?

Relapse is a significant problem, with an overall pooled prevalence of 40%. The risk factors are advanced disease and black race. The prevalence of relapse was lower in prospective studies. Future prospective studies with proper relapse definitions are needed.

INTRODUCTION

Pulmonary sarcoidosis (PS) is a nonnecrotizing granulomatous inflammatory disease that primarily affects the lungs and/or thoracic lymph nodes. It can be categorized into two types, viz. Isolated PS affects only the lungs (isolated PS) or systemic PS, which, along with the lungs, can affect several other organs, including the eyes, skin, liver, spleen, kidneys, heart, central nervous system, musculoskeletal system, bone marrow, and peripheral lymph nodes [1, 2]. Practically, this disease may have a self-limiting phenotype with a good prognosis or a progressive phenotype that portrays a poor prognosis with a significant risk of severe organ dysfunction and increased morbidity and mortality [3, 4]. Progressive disease requires optimal treatment to prevent organ dysfunction, decrease mortality and improve quality of life [5, 6]. Relapses commonly occur at various time points after withdrawal of treatment, including corticosteroids (CSs) or steroid-sparing agents (SSAs), and may persist for years, adversely affecting the prognosis of the disease [7-10].

METHODS

Study Protocol and Registration

We performed a systematic review and meta-analysis following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines (www.prisma-statement.org). The study protocol was registered with PROSPERO

Definitions of sarcoidosis states

Relapse: (i) worsening of pulmonary/extrapulmonary symptoms and radiology postremission requiring retreatment; (ii) worsening of functional/biological features; (iii) exclusion of alternative causes.

Progression: Worsening of clinical, radiological, functional, or biological markers from baseline, including new organ involvement despite optimal treatment

***Exacerbation**:* Acute disease flare-up during treatment tapering/withdrawal.
***Remission**:* Sustained (1–3 months) resolution of symptoms, stabilized radiology, and normalized pulmonary functions/serum biomarkers. Figure 6 (c)

Search strategy:
To align with the MOOSE guidelines and match the PRISMA flow diagram (Figure 1), we conducted a comprehensive search by two qualified reviewers: ZH and NKT. Discrepancies were resolved by a third reviewer (AN).
The following databases were searched: PubMed, Embase, Scopus, Google Scholar, ClinicalTrials.gov, and PROSPERO (from inception to 31 January 2025). The specific search terms used for each database are listed in the supplementary material. Boolean combinations of MeSH/Emtree terms were used. The total number of records identified was 1432 (through electronic databases and manual searches of references/citations, gray literature via Google Scholar, and conference abstracts (ATS/ERS)). The results were imported into EndNote 25, where duplicates were discarded (n=112 removed). Records screened: 1320 (title/abstract).

Additional efforts: Authors were contacted for missing data. For non-English articles, abstracts were screened via machine translation and excluded if they were unavailable in English or irrelevant (included in overall exclusions).
During the initial screening phase, 1241 records were excluded, such as those that were nonobservational or irrelevant. Next, 79 full-text articles were assessed for eligibility. Among these, 29 articles were excluded, including 25 due to missing clear relapse data and 4 because the full text was unavailable even after the authors or the journal were contacted. (Details of the excluded studies are provided in the supplement.)
Included studies: 50 (for qualitative/quantitative synthesis).
(Figure 1). Two authors (NKT and ZH) independently screened the titles/abstracts and reviewed the full texts against the eligibility criteria. Disagreements were resolved through discussion, with unresolved issues adjudicated by a third author (AN). Reference lists and citations were manually searched for additional studies.

Inclusion and Exclusion Criteria:
Inclusion:
(i) Full-text observational studies (prospective/retrospective cohorts) in peer-reviewed journals on relapse in confirmed pulmonary sarcoidosis patients (isolated/multisystem) in adult or pediatric populations
(ii) Data on the proportion of relapses among treated patients (CSs/SSAs), including the time to relapse, were collected.
(iii) Reporting of risk factors (e.g., stage, treatment).

Exclusion (with Justifications):
- Non-peer-reviewed/grey without validation (methodological rigor).
- Reviews/editorials (primary data focus).
- Case reports/series (<10 patients; insufficient for prevalence).
- Missing data (prevents pooling; authors contacted).
- Nonpulmonary sarcoidosis (irrelevant to question).

This strategy ensures transparency and bias minimization.

Data Extraction:

The authors NKT and ZH extracted data from the study texts and supplementary materials via Excel 365, including author details, publication year, country, study design, patient demographics, sarcoidosis organ involvement, treatment, remission/relapse timing, and PS diagnosis criteria. The extracted variables included age (continuous), sex (binary), and ethnicity (categorical: Black, White, other). Radiographic stages followed scoring criteria (I–IV). Acute worsening during treatment changes was classified as relapse if reported as such, although this variability was noted as a limitation.
(Supplementary Table 2)

Subgrouping of Studies:
The studies were categorized into the following subgroups: (i) study type, geographical location, and time period; (ii) patient age, sex, and ethnicity; and (iii) radiographic stages of PS [11]. (iv) Treatment types (CS, SSA, or combined CS+SSA) and (v) isolated PS and multiorgan PS.

Assessment of Quality:
We selected the Hoy et al. (2012) risk of bias tool [12]. over the nine-item JBI Checklist [13]. Owing to its focus on prevalence-specific biases and validated, high-interrater-reliability framework, it is ideal for assessing prevalence studies in this meta-analysis. The tool employs a four-point response system ("yes," "no," "unclear," "not applicable") to evaluate 10 characteristics. Studies earn one point per "yes" response, with scores ranging from 0 to 10. Scores ≥ 5, validated as indicating good quality, denote a lower risk of bias suitable for meta-analyses, although contextual factors may classify some studies as moderate risk.

Statistical analysis:
We used primarily STATA 18.0 (StataCorp, College Station, TX) and R (version 4.5.1, metafor version 4.8-0) for the statistical analysis. Prevalence was calculated as proportions with 95% confidence intervals (CIs) via the DerSimonian–Laird random effects model [14]. The restricted-maximum likelihood method was used for dichotomous outcomes because of its robustness with sparse data and heterogeneity. Cochrane's Q was used to assess subgroup differences in pooled proportions across study designs. Pooled LORs with 95% CIs were calculated via a random effects model with the restricted-maximum likelihood method.

Subgroup analysis: Continuous variables were evaluated via the empirical Bayes method and are reported as the mean differences with 95% CIs. Continuous variables (e.g., age) were analysed as continuous variables to avoid loss of information from categorization, with mean differences reported for age comparisons. For subgroup comparisons, the Z test was used for two groups, and the ANOVA-equivalent Q test was used for more than two groups.

Meta-regression: To account for multiple hypotheses across risk factors (e.g., age, sex, race, radiographic stage, and treatment type), p values were interpreted cautiously, and meta-regression was used to confirm the robustness of the significant findings [15].

Heterogeneity: The amount of heterogeneity, τ^2, was estimated via the restricted maximum likelihood estimator [16]. In addition, the Q test for heterogeneity and the I^2 statistic were reported [17]. If heterogeneity was detected (i.e., $\tau^2 > 0$), a prediction interval for the true

outcomes was calculated. Proportions were compared via LORs; if the 95% CI included zero, the difference was considered nonsignificant. To visually evaluate heterogeneity and outliers among the included studies, we employed Baujat plots and Galbraith plots. Galbraith plots are scatter plots that visualize the standardized residual on the y-axis in relation to its reciprocal standard error on the x-axis [18]. In a Boujat plot, the horizontal axis represents each study's contribution to the overall Q statistic, whereas the vertical axis indicates its influence on the summary effect [19].

Publication Bias:
We assessed publication bias visually via visual inspection of the funnel plot and objectively with Egger's and Begg's tests [20, 21].

Sensitivity analysis: As we expected to find significant heterogeneity, we planned a sensitivity analysis by removing all the factors that could affect the pooled estimate of relapse. To evaluate the robustness of the pooled relapse prevalence estimate, we conducted sensitivity analyses by (1) removing outliers, both by Boujat and Gabrieth plots; (2) performing leave-one-out analysis to check whether any single study unduly influenced pooled estimates; (3) excluding studies without an explicit relapse definition; (4) excluding studies with fewer than 50 patients to mitigate potential small-study effects, which may introduce or exacerbate heterogeneity; (5) excluding studies with a pediatric population, to determine true adult prevalence; (6) excluding studies with lower quality, i.e., moderate bias risk; and (7) applying the Freeman–Tukey transformation to stabilize variance and normalize data, improving reliability.

GRADE: Certainty was assessed via the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, adapted for prevalence studies [22].

RESULTS

Study characteristics:
Of the 50 studies, 18 were from Europe, 18 from Asia, 12 from North America, and 2 from Africa. Twenty-nine studies were retrospective, and 21 were prospective. Studies were also classified on the basis of the availability of a relapse definition (Table 1). Among these, 5 studies focused on pediatric populations, which were retained per the inclusion criteria allowing for adult or pediatric cohorts to capture the full spectrum of pulmonary sarcoidosis relapse data across age groups. One study was available through machine translation. A consistent definition of relapse was utilized in 22 studies, whereas other authors relied on clinical observations. (Supplementary Table 1)

Quality:
A review of study quality revealed that 62% (31 of 50 studies) presented a low risk of bias, 38% (19 of 50 studies) demonstrated a moderate risk of bias, and no studies were classified as having a high risk of bias. These variations stem from a lack of proper definitions for relapse or improper reporting of various parameters and their retrospective design. (Table 3)

Relapse:

Prevalence: Among the 5,978 patients across 50 studies, 3,646 were followed up posttreatment, with 1,437 experiencing relapses. The pooled prevalence of relapse was 0.40 (95% CI: 0.34, 0.46), ranging from 10% to 87.5%. (Figure 2)
Types: Most relapses (54%) were clinical, radiological, functional, or based on biomarkers, and 30% were undefined [Figure 6(a)].
Timing: The timing of relapse was mentioned in only 58% of the studies. The overall time to relapse ranged from one month to 60 months. The median time to relapse ranged from 3 (IQR 1.8–6.5) to 13 (IQR 9.5–31.5) months [Figure 6(b)].

Heterogeneity: Substantial heterogeneity was observed in the incidence of relapse, as evidenced by Cochran's Q test ($Q(49) = 1029$, $p < 0.001$). The estimated variance of the true effect sizes was $\tau^2 = 0.04$, with a heterogeneity index of $I^2 = 94\%$. However, the 95% prediction interval for the true outcomes ranged from 0.008--0.787, and this positive range suggests that despite the heterogeneity, the true outcomes of the studies generally align with the direction of the estimated average outcome. Clinically, we were expecting high heterogeneity, as we made an effort to include the maximum number of studies. The assessment of heterogeneity via the Baujat plot [Figure 5 (a)] identified different influential studies; notably, study 34 had the greatest influence on the overall pooled effect ($y \approx 0.12$), alongside studies 24, 48, 41, and 45, which highly contributed to heterogeneity ($x > 2$). The Galbraith plot [Figure 5 (b)] revealed moderate heterogeneity with outliers in studies 6, 19, and 31 positioned outside the 95% confidence interval, suggesting that these factors contribute disproportionately to variability. Sensitivity analyses excluding these Baujat-highlighted outliers reduced I^2 by 5%, with minimal shifts in the pooled estimate, confirming overall robustness. Further detailed statistical details have been added to the supplement.

(Table 1, Supplementary Figure 1)

Patients' mean age, sex, and ethnicity:
In studies with data available for two groups, the pooled log odds ratios (LORs) for relapsed versus nonrelapsed patients were not significantly different for mean age [-0.01 (95% CI: -1.47, 1.46); p=0.99] or sex [0.19 (95% CI: -0.12, 0.49); p=0.23]. The mean difference in age between the relapse group and the nonrelapse group was -0.01 (95% CI: -1.47, 1.46); p=0.99. After the five paediatric studies were separated, the relapse prevalence was 0.40 (95% CI: 0.34, 0.46) in adults and 0.34 (95% CI: 0.18, 0.51) in children (Supplementary Fig. 3). Compared with white patients, black patients had a pooled LOR of 0.91 (95% CI: 0.44, 1.37), with a p value of <0.001 indicating statistical significance. [Figure 2 (b)]

Geographic location and year of publication of studies:
No significant difference was found in the pooled proportions of relapses between Asian (N=18: 0.34, 95% CI: 0.26, 0.41) and non-Asian studies (N=32: 0.43, 95% CI: 0.35, 0.51; p=0.08) (Figure 3, Supplementary Fig. 8). or between studies conducted before 2000 CE (N=23: 0.36, 95% CI: 0.29, 0.42) and those conducted after 2000 CE (N=27: 0.44, 95% CI: 0.34, 0.54; p=0.16) (Figure 3, Supplementary Fig. 9).

Radiographic Staging of Disease
In studies with data available for two groups, the pooled LORs of relapse were greater for stage IV disease than for stage I disease [1.04 (95% CI: 0.25, 1.83); p=0.01] and for stage II and III disease than for stage I disease [0.55 (95% CI: 0.07, 1.03); p=0.02]. No significant

difference was found for stage II and III vs. stage IV disease [-0.54 (95% CI: -1.39, 0.31); p=0.21] [(Figure 3(a)].

Isolated PSs and Multiorgan PSs:
The pooled proportions of relapses in patients with isolated pulmonary sarcoidosis (PS) and multiorgan PS were not significantly different [0.35 (95% CI: 0.25, 0.46) vs. 0.41 (95% CI: 0.34, 0.48); p=0.35] [(Figure 3(b)].

CS, SSA and combined treatment (CS+SSA):
Corticosteroids (CSs) were used in 70% of the studies, whereas steroid-sparing agent (SSA) and combined CS+SSA treatment were each used in 15% of the studies. The pooled proportions of relapse did not significantly differ across treatments: CS: 0.40 (95% CI: 0.33, 0.47); SSA: 0.47 (95% CI: 0.27, 0.66); combined CS+SSA: 0.29 (95% CI: 0.19, 0.39); p=0.11. Compared with the CS (0.40) and SSA (0.47) treatments, the combined CS+SSA treatment had the lowest pooled proportion of relapses (0.29, 95% CI: 0.19, 0.39). [(Figure 3(c)]

Sensitivity analysis

We assessed the robustness of the pooled relapse prevalence estimate in pulmonary sarcoidosis patients via a random-effects REML model across 50 studies. Sensitivity analyses demonstrated the following results:

- After outliers identified through the Baujat plot were removed, the pooled prevalence was 0.35 (95% CI: 0.30, 0.40), with persistent heterogeneity I^2 of 88% [Supplementary Figure 7 (a)], whereas the pooled prevalence of outliers identified via Baujat and Galbraith was 0.38 (95% CI: 0.32, 0.43, I^2 90%) [Supplementary Figure 7 (b)].
- For studies with a relapse definition (N=22), the proportion was 0.38 (95% CI: 0.30, 0.45), and for studies without a relapse definition (N=28), it was 0.41 (95% CI: 0.33, 0.50) (Supplementary Figure 5).
- For assessing quality, the proportion of studies with low bias risk (N=31) was 0.38 (95% CI: 0.32, 0.45), and for studies with moderate bias risk (N=19), it was 0.42 (95% CI: 0.31, 0.53) (Supplementary Figure 6).
- To mitigate the small sample effect, we excluded studies with <50 patients (N=26). Relapse rates were similar between studies with 50+ patients (N=24) and those with fewer than 50 patients (Supplementary Figure 7).
- Leave-one-out analysis revealed stable proportions ranging from 0.39--0.41, with 95% CIs ranging from 0.33--0.46 (Supplementary Table 4). The lowest prevalence was obtained by omitting studies 34, 48, 24 and 41.
- The Freeman–Tukey arcsine transformation yielded a proportion of 0.40 (95% CI: 0.33, 0.46) (Supplementary Table 3).

Despite high heterogeneity (I^2=94%, Tau^2=0.05, chi^2=1029, p=0.0), the pooled relapse proportion remained stable at 40%. However, it was reduced by 8% in prospective studies (I^2=86%) (Figure 5, Table 2).

Study No.	Study	Country	Design	Total Patients	Follow-up Patients	Relapsed Patients	Time to Relapse (Months)	Definition of Remission	Relapse definition
1	Bouchut et al. (2024)[22].	France	Retrospective	175	173	91	48-156	NA	Yes*
2	Guliyeva et al. (2024)[23].	Turkey	Retrospective	52	52	14	2-60	Clinical normalization	NA
3	Dhooria et al. (2023)[24].	India	Prospective	86	86	39	6-15	NA	Yes
4	Ozdemirel et al. (2023)[25].	Turkey	Retrospective	73	73	16	NA	NA	NA
5	Spyropoulos et al. (2022)[26].	Greece	Prospective	147	147	42	NA	NA	NA
6	Madan et al. (2022)[27].	India	Prospective	327	327	73	NA	NA	NA
7	Sakkat et al. (2022)[28].	Canada, UK	Retrospective	33	11	7	2-10	Clinical & biological normalization	NA
8	Morar et al. (2022)[29].	South Africa	Retrospective	102	89	54	NA	NA	NA
9	Feng et al. (2022)[30].	China	Retrospective	432	123	24	NA	NA	Yes
10	Gavrysyuk et al. (2021a)[31].	Ukraine	Prospective	143	84	28	6-12	Clinical & radiological normalization	Yes
11	Murata et al. (2021)[32, 33].	Japan	Retrospective	103	103	23	NA	NA	Yes
12	Gavrysyuk et al. (2021b)[33].	Ukraine	Prospective	108	108	56	6-12	NA	Yes
13	Fang et al. (2019)[34].	China	Retrospective	60	11	2	1-30	NA	Yes
14	Nath et al. (2019)[35].	India	Retrospective	120	120	29	2-9	Clinical, radiological, & biological normalization	Yes
15	Zheng et al. (2019)[36].	China	Retrospective	203	96	30	1-36	Clinical & radiological normalization for at least 06 months after treatment withdrawal.	Yes
16	Ozyilmaz et al. (2018)[37].	Turkey	Prospective	91	29	13	NA	NA	NA

17	Belhomme et al. (2018)[38].	France	Retrospective	80	34	10	NA	NA	Yes
18	Chen et al. (2018)[39].	China	Retrospective	23	23	12	NA	Clinical, & radiological normalization	Yes
19	Mañá et al. (2017)[40].	Spain	Prospective	640	266	30	NA	NA	Yes
20	Maturu et al. (2016)[41].	India	Prospective	27	27	10	3-12	Clinical, & radiological normalization	Yes
21	Liu et al. (2016)[42].	China	Prospective	42	42	20	NA	NA	Yes
22	Polverosi et al. (2014)[43].	Italy	Retrospective	56	44	9	NA	NA	NA
23	Vorselaars et al. (2014)[44].	Netherlands	Retrospective	47	47	29	8-14	NA	Yes
24	Sharma et al. (2003)[45].	India	Retrospective	56	53	40	On CS Taper	NA	NA
25	Kiper et al. (2001)[46].	Turkey	Retrospective	15	15	6	NA	Clinical, radiological, & biological normalization	Yes
26	Sharma et al. (2001)[47].	India	Prospective	106	85	21	NA	NA	Yes
27	Baculard et al. (2001)[48].	France	Retrospective	21	21	4	On CS Taper	Radiological, & PFT normalization	Yes
28	Muller-Quernheim et al. (1999)[49].	Germany	Prospective	11	11	3	8-22	NA	NA
29	Kim et al. (1999)[50].	Korea	Prospective	27	27	4	On CS withdrawal	NA	NA
30	Baltzan et al. (1999)[51].	Canada	Prospective	23	18	8	NA	NA	Yes
31	Rizzato et al. (1998)[52].	Italy	Retrospective	702	82	30	12-36	NA	NA
32	Wyser et al. (1997)[53].	South Africa	Prospective	37	16	7	4-48	NA	Yes
33	Gottlieb et al. (1997)[54].	Israel	Prospective	337	221	86	2-12	NA	Yes
34	Lower et al. (1995)[55].	USA	Retrospective	105	40	35	NA	NA	Yes
35	Takada et al. (1993)[56].	Japan	Retrospective	295	76	36	On CS withdrawal	NA	NA
36	Chadelat et al. (1993)[57].	France	Prospective	8	8	2	NA	NA	NA

37	Prior et al. (1991)[58].	UK	Prospective	25	25	6	NA	NA	NA
38	Rizzato et al. (1991)[59].	Italy	Retrospective	40	40	4	On CS withdrawal	NA	NA
39	Baumann et al. (1990)[60].	USA	Retrospective	15	15	10	3-6	NA	NA
40	Lower et al. (1990)[61].	USA	Retrospective	15	14	5	NA	NA	NA
41	Johns et al. (1986)[62].	USA	Retrospective	181	171	128	1-2	NA	NA
42	Wallaert et al. (1986)[63].	France	Prospective	12	12	8	12-18	NA	NA
43	Turner-Warwick et al. (1986)[64].	UK	Prospective	32	32	4	NA	NA	NA
44	Eule et al. (1986)[65].	Germany	Prospective	172	110	24	NA	NA	NA
45	Johns et al. (1983)[66].	USA	Retrospective	103	99	74	On CS taper or withdrawal	NA	NA
46	Rohatgi et al. (1981)[67].	USA	Prospective	35	20	6	On CS Taper	NA	NA
47	Johns et al. (1976)[68].	USA	Retrospective	192	146	102	On CS withdrawal	NA	NA
48	Johns et al. (1974)[69].	USA	Retrospective	152	145	113	On CS taper or withdrawal	NA	NA
49	Emirgil et al. (1969)[70].	USA	Retrospective	84	22	6	On CS Withdrawal	NA	NA
50	Morse et al. (1961)[71].	USA	Retrospective	7	7	4	1-3	NA	NA

Table 1: Characteristics of the Included Studies

Biological tests: Serological, histological or other in vitro laboratory tests for determining the sarcoid activity of the organs involved. CS: Corticosteroids, NA: Not Available, PFT: Pulmonary Function Test, PS: Pulmonary Sarcoidosis, SSA: Steroid-Sparing Agents, Relapse definition: Yes (available). Studies 24, 34, 48, 41, 45, and 24 were outliers, and 2, 25, 27, 37 and 39 were pediatric.

Meta-regression: The meta-regression findings suggest that the covariates account for a limited amount of the variance (R-squared=7.38%), with the model lacking statistical significance (Wald chi^2 (7) = 9.38, p = 0.227), implying insufficient explanation of the observed heterogeneity in relapse proportions. Within the set of moderators, only study

design (prospective vs retrospective) was a statistically significant predictor (coefficient = 0.142, p = 0.025), suggesting that retrospective designs are linked to increased relapse estimates relative to prospective designs. Residual heterogeneity remained high (I^2 = 92%, tau^2 = 0.036, Q residual = 567.32, p < 0.001), indicating substantial unexplained variation, likely due to unmeasured factors such as patient demographics, treatment protocols, or follow-up durations.
(Supplementary Table 2)

Publication bias: The funnel plot was symmetrical, indicating that there was no visual publication bias. Similarly, the regression-based Egger's test [intercept=0.60 (95% CI: -2.07, 3.27), p=0.645] and nonparametric Begg's test (Kendall's tau=0.07, p=0.465) showed no evidence of publication bias [Figure 4(b)]. There was no bias due to missing data, as we excluded studies with missing data. Given the absence of asymmetry, small-study effects were dismissed, leading to the omission of subsequent planned analyses, such as trim-and-fill analysis.

GRADE assessment: The GRADE assessment rates the overall incidence of relapse in pulmonary sarcoidosis patients (40% of 50 studies, 3,646 patients) as low certainty owing to the risk of bias and high inconsistency (I^2 = 94%). Prospective studies (21 studies) revealed moderate certainty, whereas the risk of relapse in black patients was also moderate, with a large effect (LOR 0.91) despite bias concerns. (Supplementary Table 5)

DISCUSSION:

This study, the first systematic review and meta-analysis on the global incidence of pulmonary sarcoidosis (PS) relapse, analysed 50 studies with 3,646 follow-up patients. The key findings included a 40% pooled relapse incidence (range: 10%–87.5%).
Some review articles in the literature have reported that the prevalence of PS relapse ranges from 13–80%, which is consistent with our findings [7, 10, 72]. The variability in relapse prevalence observed in our study, as well as in these review articles, may stem from inconsistent definitions of relapse, remission, and PS diagnosis.

The timing of relapse after remission varies depending on disease severity and treatment efficacy. Our meta-analysis revealed that the minimum and maximum median times to relapse were 3 and 13 months, respectively. Most relapses occurred within the first three years, with approximately 10% occurring in the fourth or fifth year, suggesting the need for active patient follow-up for five years. Similarly, several studies in the literature report relapse occurrence from 1–24 months after remission and, in certain cases, after 24 months of treatment withdrawal [6, 10, 54]. In accordance with our data, one study reported no further relapses in

patients who remained asymptomatic for three years after prednisone withdrawal [52]. Relapses often occur months after CS reduction or withdrawal, specifically 3 to 6 months after total steroid discontinuation, necessitating prolonged monitoring in trials, as immediate postwithdrawal assessments may underestimate relapse rates [24].

The type of relapse, characterized by clinical, radiological, pulmonary function, or biochemical parameters, is clinically important for improving the prognosis of patients with pulmonary sarcoidosis. Over 60% of patients experienced symptomatic relapses with radiological, functional, or biochemical features, whereas approximately 10% experienced asymptomatic relapses, with the remainder undefined or based on other criteria. In the literature, most studies report clinical and/or radiological relapses, some report functional or biochemical relapses, and many do not specify relapse types [5, 73]. On the basis of these findings, relapse diagnosis should not rely solely on clinical parameters but should include radiological, functional, or biochemical parameters. Asymptomatic relapses, detected by biomarkers, may sometimes precede clinical and/or radiological signs, facilitating early detection and management of relapses.

Relapse-associated risk factors are crucial for determining treatment strategies for this disease but remain largely unknown. In this study, we identified several potential risk factors for PS relapse. We observed that higher radiographic scoring stages of the lungs (i.e., stages II, III, and IV) are important risk factors for PS relapse. The lower probability of disease resolution ranging from 0% (stage IV) to 10–40% (stages II and III) than from 50–90% (stage I) supports our findings [74]. The higher relapse rate observed in stage IV sarcoidosis patients (pooled LOR: 1.04, 95% CI: 0.25, 1.83) may partly reflect chronic, nonresolving disease rather than true relapse, particularly given the retrospective nature of many included studies (58% retrospective). Some stage IV patients may remain stable without active biomarkers, suggesting that selection bias could overestimate relapse rates in this group. This distinction warrants cautious interpretation of our findings. Furthermore, prior studies, including ours and others, have reported higher relapse rates in patients with advanced radiographic stages, supporting these findings [26, 35, 60]. Parenchymal damage or fibrosis in advanced stages may reflect persistent inflammation, increasing the likelihood of relapse. According to a previous study, patients diagnosed with chronic or fibrotic sarcoidosis (stage IV), with fibrocystic malformation, pulmonary hypertension, or chronic pulmonary aspergillosis, are more prone to relapse, whereas individuals with mild forms of the disease or isolated lymphadenopathy face a reduced risk [82]. According to the multinational Delphi consensus study on high-resolution CT (HRCT) phenotypes in pulmonary sarcoidosis, common CT findings include perilymphatic micronodules, larger bronchovascular nodules, and consolidation in nonfibrotic phenotypes, whereas fibrotic phenotypes are characterized by bronchocentric reticulation, dense parenchymal opacification, and cavitation—features that may align with advanced scoring stages III–IV and contribute to higher relapse rates, as identified in our meta-analysis [75].

To determine whether isolated or systemic PS could be a risk factor for relapse, we compared relapse rates between these subgroups but found no significant difference. However, previous studies have shown a link between multiorgan involvement and relapse risk [33, 38]. reported

high relapse rates in patients with lung [25], heart [32], musculoskeletal system [22], and central nervous system (CNS) [28, 76] involvement, whereas the absence of erythema nodosum or peripheral adenopathy was associated with a lower likelihood of relapse [54, 77]. Relapses have also been linked to phenotypes—e.g., fibrosis prevalent in chronic (57.9%) and advanced (61.2%) phenotypes vs. asymptomatic (13.8%; P<0.001). Ocular involvement was greater in relapsing patients (P<0.001). There was no significant association with age or sex, but cutaneous involvement favoured acute onset and remission[26].

We investigated whether treatments for pulmonary sarcoidosis (PS), including corticosteroids (CSs, e.g., prednisone, prednisolone, and methylprednisolone), immunosuppressive agents (SSAs, e.g., methotrexate, azathioprine, and infliximab), or combined regimens (CSs + SSAs), influence the incidence of relapse. For patients who require therapy, CSs are the cornerstone of treatment for pulmonary sarcoidosis, typically starting at 40 mg/day and tapering to 10–15 mg every other day over 6–9 months [78]. In addition, both the ERS and BTS guidelines advise the addition of methotrexate (ERS: 10–15 mg/week; BTS: starting at 5–10 mg/week and increasing to 15–20 mg/week) for patients with ongoing disease or glucocorticoid side effects [7, 79, 80]. However, several studies have reported that CS monotherapy is a major risk factor for PS relapse [10, 32, 54, 81]. However, relapse is common with tapering (e.g., studies have shown that benefits are short-lived postdiscontinuation, and a dose of >20 mg prednisone per day offers no additional benefit for pulmonary disease but increases side effects (e.g., weight gain, osteoporosis), potentially driving nonadherence and relapse [6]. Approximately 50% of patients relapse after the cessation of immunosuppression. A high relapse rate in corticosteroid (CS)-treated pulmonary sarcoidosis patients was observed when the CS-treated group was not compared with the non-CS-treated group. Most CS-treated patients had severe disease at baseline, suggesting that high disease severity, not CS therapy, may drive the elevated relapse rate [54]. A recent report showing comparable outcomes between patients with CS- versus MTX-treated sarcoidosis further supports this notion [82]. Similarly, another recently published RCT of 138 patients, PREDMETH, evaluated two regimens for treatment-naïve symptomatic pulmonary sarcoidosis. In that study, the authors reported a “noninferior” difference in the FVC % predicted and the KSQ-L [83]. Interestingly, some reports have revealed a significantly lower relapse rate and better disease outcomes in patients receiving combined treatment (CS + MTX) than in those receiving CS treatment alone [84-86]. Withdrawal of methotrexate therapy after 2 additional years for chronic sarcoidosis was associated with 80% reinstitutions of systemic therapy [6].

Owing to limited data (15% of studies), SSAs were grouped together, despite their heterogeneity (e.g., methotrexate vs. TNF-alpha inhibitors), potentially obscuring specific relapse risks. Pooled relapse rates were similar across the CS, SSA, and combined treatments, indicating that there was no association between treatment type and relapse. Although not significant, the lower relapse rate with combined treatment (0.29) than with CS (0.40) or SSA monotherapy (0.47) suggests a possible synergistic effect, particularly in severe cases, warranting further exploration. In alignment with ERS guidelines, combined CS + SSA (e.g., methotrexate) may offer synergistic benefits in severe PS, as evidenced by reduced CS doses and improved PFTs. CSs are suggested as initial therapies for high-risk PS (e.g., reduced

FVC/DLCO, fibrosis, and pulmonary hypertension) to preserve FVC and reduce mortality/disability [6].

Relapse frequencies might vary depending on whether remission occurred naturally or was brought on by treatment; the latter could carry a greater risk, especially after the cessation of corticosteroids. However, this study focused solely on treated patients [54].] Residual disease activity (subclinical posttreatment activity) might drive relapse in pulmonary sarcoidosis patients. Posttreatment residual sarcoid activity is significantly more common in patients who relapse than in those who do not relapse [52]. The likelihood of pulmonary sarcoidosis relapse may depend on residual sarcoid activity at treatment withdrawal: moderate activity may cause early relapses, mild activity may cause late relapses, and minimal/no activity may cause no relapses. Treatment type (70% CS, 15% SSA, 15% CS+SSA) and duration influence relapse timing (median: 3–13 months), with premature cessation linked to earlier relapses. Reliable methods to measure sarcoid activity during treatment and follow-up are needed to optimize treatment duration and timing for tapering/withdrawal to minimize relapses. As per current practice, for patients on maintenance methotrexate experiencing relapse, a two-week trial of prednisone 20 mg/day followed by a rapid taper is suggested. Frequent relapses may indicate the need for alternative immunosuppressive agents [87]. A recent double-blind RCT demonstrated the role of Efzofitimod, an immunomodulator that binds to neuropilin 2, which is upregulated on immune cells in response to lung inflammation, and demonstrated that it was steroid sparing (22% reduction) and had a better safety profile and lung function trends [88]. Sirolimus might be another safe and effective treatment option for patients with persistent glucocorticoid-refractory sarcoidosis [89].

Compared with white race, black race is a well-documented risk factor for sarcoidosis and is associated with greater disease severity [90, 91]. Compared with Caucasians, African Americans exhibit a substantially increased mortality risk (12 times higher, younger age at death) [92]. Our observation agrees with the high severity of sarcoidosis observed in the Black population [83, 86]. There are also high relapse rates within this group [29, 66, 70]. The increased relapse risk in Black patients may reflect genetic predispositions (HLA-DRB1*14 allele) or disparities in healthcare, warranting further investigation [93].

There was no effect of age or sex. We classified studies published before 2000 CE because we hypothesized that diagnostic modalities for the diagnosis of sarcoidosis would become more advanced, but no difference was found. Similarly, Asian or non-Asian studies did not show any difference, suggesting that the approach to relapse is the same throughout the globe.

Limitations and Mitigations: The studies exhibited high heterogeneity, with lower heterogeneity in prospective designs ($I^2 = 86\%$) than in retrospective designs ($I^2 = 94\%$). This makes GRADE, the certainty of evidence for the pooled relapse incidence, and the prospective design low, moderate for black patients. Despite being commonly criticized, heterogeneity is necessary. Understanding clinical variations is crucial [70], and recognizing these differences in treatment outcomes offers benefits [71]. Moreover, if present, heterogeneity has the potential to render the results more applicable to a broader spectrum of individuals and circumstances [72]; therefore, investigating heterogeneity is necessary [86].

We hypothesized that removing outliers would mitigate heterogeneity; therefore, we implemented a dual strategy involving a Baujat plot to address overinfluential studies and a Galbraith plot to identify heterogeneity related to methodological artifacts or subgroup effects. However, removing these outliers decreased heterogeneity by 5%, with a minimal effect on pooled estimates. Sensitivity analyses with high-quality studies, excluding studies with a small sample size (<50) to exclude studies without definition, confirmed robustness, with estimates ranging from 0.35 (outliers removed) to 0.41, and most analyses were stable at approximately 0.38–0.40. The Freeman–Tukey arcsine transformation provides superior variance stabilization, narrower confidence intervals, and better coverage for extreme proportions in meta-analysis, whereas leave-one-out enhances robustness by detecting influential studies, both outperforming DerSimonian–Laird in handling heterogeneity and bias. The pooled estimate remains stable, demonstrating minimal shifts, such as I^2=88% postoutlier removal, indicating a lack of significant bias and suggesting genuine clinical diversity in sarcoidosis relapses.

Meta-regression is another way to manage meta-analysis differences by studying the link between study-level covariates and effect sizes to find and measure sources of variation. This suggests that while study design emerges as a key moderator—with retrospective studies potentially inflating relapse estimates owing to selection bias—the substantial unexplained heterogeneity underscores the multifaceted nature of sarcoidosis relapse, likely driven by clinical diversity in patient profiles and management practices.

Prospective studies showed less heterogeneity (by 5%), suggesting that stricter follow-up reduces variability. According to the quality assessment of the studies, no studies had a high risk of bias; 31 had a low risk, and the rest had a moderate risk of bias. Funnel plot inspection and Egger's/Begg's tests indicated no publication bias.

In conclusion, this systematic review and meta-analysis establishes a global pooled relapse incidence of 40% in pulmonary sarcoidosis patients and highlights the critical role of advanced radiographic staging and racial disparities, particularly among Black patients, in driving PS relapse risk while emphasizing the potential synergistic benefits of combined corticosteroid and immunosuppressive therapies. Additionally, the findings emphasize the need for prospective studies to further investigate modifiable risk factors, which could reduce heterogeneity and enhance personalized treatment strategies.

Future directions: Sarcoidosis research has exhibited considerable heterogeneity, which impedes accurate assessment, prognostication, treatment, and follow-up of patients. Using standard diagnostics and monitoring could lower heterogeneity. Initially, the uniform definition presented in this manuscript must be established; this could be validated through upcoming clinical trials that utilize outcomes outlined in SCOUT, representing an agreement among patients and health professionals regarding crucial outcomes for future research [94, 95]. The observed elevated heterogeneity demonstrates global disparities (e.g., increased relapse rates in non-Asian groups), which therefore impacts the development of public health strategies. For places with high prevalence rates, such as Europe or the US, bolstering long-term monitoring of high-risk groups might be helpful. This emphasizes the need for clinical trials on modifiable

risks, such as improved tapering methods or steroid-sparing medications, to enhance treatment and mitigate the approximately 40% incidence of relapse. Additionally, consistent monitoring is needed even for asymptomatic patients to prevent asymptomatic relapses and facilitate early detection, thus enabling prompt intervention.

I. Relapse:

A. **Clinical Criteria** (Require measurable worsening in ≥1 domain) *

a. Recurrence of clinical symptoms quantified using validated tools
   - i. Documented worsening on the Fatigue Severity Scale (FSS) or any similar for fatigue
   - ii. Increase in cough, or chest pain, which significantly impairs quality of life
   - iii. ≥2-point worsening on the Medical Research Council (mMRC) scale or similar

b. Systemic manifestations defined as new/worsening organ involvement requiring intervention

AND/OR

B. Lab Criteria

a. Presence of radiological findings quantified by scoring
   - i. New or progressive lymphadenopathy, nodules, infiltrates, or lesions on chest X-ray, CT, or HRCT
   - ii. With ≥ specified threshold increase using CT Activity Score (CTAS) or equivalent objective validated imaging scale

b. With or without elevated biomarkers**
   - i. Serum ACE > upper normal limit
   - ii. Inflammatory markers like CRP/ESR elevated beyond baseline
   - iii. Alkaline phosphatase rise
   - iv. Hypercalcemia >10.5 mg/dl
   - v. Hypercalciuria >300 mg/24 h)

c. Accompanied by deterioration in pulmonary function tests with specific thresholds
   - i. FEV1 predicted, FVC% predicted, or DLCO% predicted: ≥10% absolute decline
   - ii. ≥150 mL absolute FVC change
   - iii. Six-minute-walk distance change > 50 meters AND/OR 5% desaturation

Duration: Occurring **at least 4–6 weeks** (up to 3–6 months for delayed events) after complete withdrawal of immunosuppressive therapy, following documented remission; **monitor postwithdrawal for ≥6 months-1 year**

Exclusion of Alternative Causes: Infections, heart failure, pulmonary embolism, or other confounders (via clinical evaluation, cultures, echocardiography, or D-dimer testing)

Operational Definition *(For clinical practice):* Relapse is defined by the need for an increase/addition of anti-inflammatory therapy **lasting >2 weeks** (e.g., prednisone dose escalation >2 weeks or addition of methotrexate)

---

*For clinical trials, tools such as the ≥4-point worsening in the King's Sarcoidosis Questionnaire-Lung (KSQ-Lung) for cough/dyspnea and the Fatigue Assessment Scale (FAS) are preferable.

**Interpret cautiously as changes may reflect corticosteroid withdrawal rather than true relapse; do not use as standalone criterion

Remission:

A. Clinical: The sustained (≥ 6 months) absence of symptoms (e.g., stable FAS, mMRC scale, no symptom which interferes with QOL at baseline); resolution of radiological abnormalities.
B. Lab: Normal biochemical parameters:
    a. Serum ACE within normal range
    b. No elevated inflammatory markers
    c. Alkaline phosphatase: normal
    d. No Hypercalcemia/hypercalciuria

Require no ongoing immunosuppressive therapy beyond low-dose maintenance if applicable

Points for Clinical Practice

1. The relapse rates of pulmonary sarcoidosis are high, with approximately 40% of patients experiencing recurrence after treatment. High-risk groups (black patients, advanced-stage disease [II–IV]) were monitored more frequently.

2. **Risk Factors**:

- Black race (↑ odds of relapse).
- Higher radiographic stages (Scadding II–IV).
- There was no significant association with age, sex, or treatment type (CS/SSA/combined).

3. **Follow-up**: Active surveillance for ≥5 years post-treatment withdrawal is advised, as relapses typically occur within 3–13 months. At least 5 years of follow-up are needed even in asymptomatic patients.

4. **Asymptomatic Relapses**: ~10% of relapses lack symptoms; radiological/functional biomarkers are included in monitoring.

Questions for Future Research

1. **Standardized definitions**: Consensus needed for relapse, remission, and disease activity criteria.

2. **Biomarkers**:

- Can residual disease activity (e.g., hypercalciuria, PET-CT) predict relapse timing/severity?
- Role of FDG-PET

3. **Treatment Strategies**:

- Does combined CS+SSA therapy truly reduce relapse risk compared with monotherapy?
- Optimal duration of maintenance therapy to prevent relapse

Figure Legends:

Figure 1: PRISMA flow diagram depicting the study selection process, including identification, screening, eligibility assessment, and inclusion of eligible studies.

Figure 2: Significant forest plots from the meta-analysis of overall relapse incidence, black race and prospective studies

Figure 3: Forest plots for stage, isolated vs multiorgan involvement and treatment

Figure 4: Sensitivity analysis: Forest plot showing the proportion of studies with 95% CIs across subgroups: design (prospective vs. retrospective), relapse definition (yes vs. no), year (after vs. before 2000), Asian vs. non-Asian, patients >50 (yes vs. no), and quality (low vs. moderate risk of bias).

Figure 5: Diagnostic plots for investigating heterogeneity and publication bias in the meta-analysis

Figure 6: Types of relapses, time to relapse, and potential trajectories of the natural disease history of sarcoidosis patients

Data availability statement: The authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.

Ethical considerations: This research did not require ethical committee approval, as it is entirely based on previously published studies.

Patient and Public Involvement Statement: This study is a systematic review and meta-analysis based on previously published data, with no new primary data collected from patients. As such, patients and the public were not involved in the design, conduct, reporting, or dissemination plans of this research.

Acknowledgements: We extend our sincere gratitude to Professor Robert P. Baughman, M.D., Department of Internal Medicine, University of Cincinnati, for his insightful guidance in initiating this meta-analysis and for his generous clinical input, as per his vast experience in this field regarding definitions of relapse and remission and proofreading the manuscript. Additionally, we thank Professor Vikas Agarwal from the Department of Clinical Immunology and Rheumatology for his valuable guidance. We acknowledge the contributions of Professor Karan Madan, Department of Pulmonary, Critical Care and Sleep Medicine, All India Institute of Medical Sciences, New Delhi, and Professor Sahajal Dhooria, Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, who kindly provided additional information about their study in response to our inquiry. We also thank Krishanu Mukhoti, Senior Resident, Department of Pulmonary Medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Shivani Srivastava, Ph.D. Scholar, and Mohammad Haider for their help in drafting the tables and manuscript formatting.

Funding: None

Conflict of interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Analysis Type	N	Pooled ES (95% CI)	I^2 (%)	τ^2
Leave-one-out	50	0.40 (0.33, 0.46)	95	0.05
Removing outliers	45	0.35 (0.30, 0.40)	89	0.02
Freeman-Tukey	50	0.40 (0.33, 0.46)	95	0.05
Prospective Studies	22	0.32 (0.30, 0.45)	88	0.03
Retrospective Studies	28	0.45 (0.33, 0.50)	97	0.04
Studies with relapse definition	22	0.38 (0.30, 0.45)	92	0.03
Follow-up > 50 studies	24	0.41 (0.33, 0.50)	97	0.04
High-quality studies	31	0.38 (0.32, 0.45)	97	0.04
Adults	45	0.40 (0.34, 0.46)	94	0.04

Table 2: Sensitivity analysis

List of acronyms used

- **ANOVA**: Analysis of variance
- **ATS**: American Thoracic Society
- **BTS**: British Thoracic Society
- **CI**: Confidence interval
- **CNS**: Central nervous system
- **CS**: Corticosteroids
- **DLCO**: Diffusion capacity of the lung for carbon monoxide
- **ERS**: European Respiratory Society
- **FDG-PET**: Fluorodeoxyglucose positron emission tomography
- **FVC**: Forced vital capacity
- **HLA**: Human leukocyte antigen
- **I^2**: Heterogeneity Index
- **IQR**: Interquartile range
- **JBI**: Joanna Briggs Institute
- **KSQ-L:**
- **LOR**: Log odds ratio
- **MeSH**: Medical Subject Headings
- **MOOSE**: Meta-analysis of Observational Studies in Epidemiology
- **MTX**: Methotrexate
- **NA**: Not available

- **PFT**: Pulmonary function test
- **PRISMA**: Preferred Reporting Items for Systematic Reviews and Meta-analyses
- **PS**: Pulmonary sarcoidosis
- **REML**: Restricted maximum likelihood
- **SSA**: Steroid-Sparing Agent
- **WASOG**: World Association of Sarcoidosis and Other Granulomatous Disorders

References:

1. Partin M, Clebak KT, Chen R, Helm M. Sarcoidosis: Evaluation and Treatment. *American family physician* 2024: 109(1): 19–29.
2. Tavana S, Alizadeh M, Mohajerani SA, Hashemian SM. Pulmonary and extra-pulmonary manifestations of sarcoidosis. *Nigerian medical journal : journal of the Nigeria Medical Association* 2015: 56(4): 258–262.
3. Judson MA. Extrapulmonary sarcoidosis. *Seminars in respiratory and critical care medicine* 2007: 28(1): 83–101.
4. Gerke AK. Morbidity and mortality in sarcoidosis. *Current opinion in pulmonary medicine* 2014: 20(5): 472–478.
5. Gerke AK. Treatment of Granulomatous Inflammation in Pulmonary Sarcoidosis. *J Clin Med* 2024: 13(3): 738.
6. Baughman RP, Valeyre D, Korsten P, Mathioudakis AG, Wuyts WA, Wells A, Rottoli P, Nunes H, Lower EE, Judson MA, Israel-Biet D, Grutters JC, Drent M, Culver DA, Bonella F, Antoniou K, Martone F, Quadder B, Spitzer G, Nagavci B, Tonia T, Rigau D, Ouellette DR. ERS clinical practice guidelines on treatment of sarcoidosis. *The European respiratory journal* 2021: 58(6).
7. Thillai M, Atkins CP, Crawshaw A, Hart SP, Ho LP, Kouranos V, Patterson K, Screaton NJ, Whight J, Wells AU. BTS Clinical Statement on pulmonary sarcoidosis. *Thorax* 2021: 76(1): 4–20.
8. Johns CJ, Michele TM. The Clinical Management of Sarcoidosis A 50-Year Experience at the Johns Hopkins Hospital. *Medicine* 1999: 78(2).
9. Shobha V. Pulmonary sarcoidosis – Predictors of relapse: Are we there yet? *Indian Journal of Rheumatology* 2019: 14(4).
10. Baughman RP, Judson MA. Relapses of sarcoidosis: what are they and can we predict who will get them? *The European respiratory journal* 2014: 43(2): 337–339.
11. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. *American journal of respiratory and critical care medicine* 1999: 160(2): 736–755.
12. Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, Baker P, Smith E, Buchbinder R. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. *Journal of clinical epidemiology* 2012: 65(9): 934–939.
13. Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. The Joanna Briggs Institute approach for conducting systematic reviews of prevalence and incidence data. *International Journal of Evidence-Based Healthcare* 2015: 13(3): 163–169.
14. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Controlled clinical trials* 1986: 7(3): 177–188.

15. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? *Stat Med* 2002: 21(11): 1559–1573.
16. Viechtbauer W. Bias and Efficiency of Meta-Analytic Variance Estimators in the Random-Effects Model. *Journal of Educational and Behavioral Statistics* 2005: 30(3): 261–293.
17. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002: 21(11): 1539–1558.
18. Galbraith RF. A note on graphical presentation of estimated odds ratios from several clinical trials. *Stat Med* 1988: 7(8): 889–894.
19. Baujat B, Mahé C, Pignon JP, Hill C. A graphical method for exploring heterogeneity in meta-analyses: application to a meta-analysis of 65 trials. *Stat Med* 2002: 21(18): 2641–2652.
20. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics* 1994: 50(4): 1088–1101.
21. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ (Clinical research ed)* 1997: 315(7109): 629–634.
22. Bouchut A, Lhote R, Maksud P, Ben Salem T, Fustier A, Moyon Q, Haroche J, Soussan M, Mathian A, Hie M, Amoura Z, Aubart FC. Prognostic value of hypermetabolic bone sarcoidosis observed by 18F-fluorodeoxyglucose positron emission tomography. *Rheumatology (Oxford, England)* 2024.
23. Guliyeva V, Demirkan FG, Yigit RE, Esen E, Bayindir Y, Torun R, Kilbas G, Gezgin Yildirim D, Otar Yener G, Cakan M, Demir F, Ozturk K, Baglan E, Yuksel S, Bakkaloglu SA, Bora Makay B, Pac Kisaarslan A, Oray M, Bilginer Y, Eker Omeroglu R, Ozen S, Sozeri B, Aktay Ayaz N. A clinical overview of paediatric sarcoidosis: Multicentre experience from Turkey. *Modern rheumatology* 2024: 34(3): 639–645.
24. Dhooria S, Sehgal IS, Agarwal R, Muthu V, Prasad KT, Dogra P, Debi U, Garg M, Bal A, Gupta N, Aggarwal AN. High-dose (40 mg) versus low-dose (20 mg) prednisolone for treating sarcoidosis: a randomised trial (SARCORT trial). *The European respiratory journal* 2023: 62(3).
25. Sahin Ozdemirel T, Akinci Ozyurek B, Tatci E, Ertan O, Akkurt ES, Senturk A, Ozmen O. Relationships Between Systemic Inflammatory Markers and 18F-FDG PET/CT Imaging and Clinical Findings in Pulmonary Sarcoidosis. *Cureus* 2023: 15(3): e36521.
26. Spyropoulos G, Domvri K, Manika K, Fouka E, Kontakiotis T, Papakosta D. Clinical, imaging and functional determinants of sarcoidosis phenotypes in a Greek population. *Journal of thoracic disease* 2022: 14(6): 1941–1949.
27. Madan K, Sryma PB, Pattnaik B, Mittal S, Tiwari P, Hadda V, Mohan A, Guleria R. Clinical Profile of 327 patients with Sarcoidosis in India: An Ambispective Cohort Study in a Tuberculosis (TB) Endemic Population. *Lung India* 2022: 39(1): 51–57.
28. Sakkat A, Cox G, Khalidi N, Larche M, Beattie K, Renzoni EA, Morar N, Kouranos V, Kolb M, Hambly N. Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis. *Respiratory research* 2022: 23(1): 54.
29. Morar R, Feldman C. Sarcoidosis in Johannesburg, South Africa: A retrospective study. *Afr J Thorac Crit Care Med* 2022: 28(4): 150–156.
30. Feng H, Yan L, Zhao Y, Li Z, Kang J. Neutrophils in Bronchoalveolar Lavage Fluid Indicating the Severity and Relapse of Pulmonary Sarcoidosis. *Front Med (Lausanne)* 2021: 8: 787681.
31. Gavrysyuk V, Merenkova I, Dziublyk Y, Morska N, Pendalchuk N, Bychenko O, Vlasova N. Efficacy and Tolerability of Methotrexate and Methylprednisolone in a Comparative Assessment of the Primary and Long-Term Outcomes in Patients with Pulmonary Sarcoidosis. Diagnostics, 2021.
32. Murata O, Suzuki K, Takeuchi T, Kudo A. Incidence and baseline characteristics of relapse or exacerbation in patients with pulmonary sarcoidosis in Japan. *Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG* 2021: 38(3): e2021026.
33. Gavrysyuk V, Merenkova I, Vlasova N, Bychenko O. Clinical Factors Associated with the Risk of Pulmonary Sarcoidosis Relapse. *Georgian medical news* 2021(313): 84–88.
34. Fang C, Zhang Q, Wang N, Jing X, Xu Z. Effectiveness and tolerability of methotrexate in pulmonary sarcoidosis: A single center real-world study. *Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG* 2019: 36(3): 217–227.

35. Nath A, Hashim Z, Khan A, Gupta M, Neyaz Z, Misra DP, Mishra R, Srivastava S. Experience of Sarcoidosis and Factors Predicting Relapse at a Tertiary Care Institute in North India. *Indian Journal of Rheumatology* 2019: 14(4).
36. Zheng Y, Wang H, Xu Q, Yan X, Zhuang Y, Jiang H, Meng F, Xiao Y, Cai H, Dai J. Risk factors of relapse in pulmonary sarcoidosis treated with corticosteroids. *Clinical rheumatology* 2019: 38(7): 1993–1999.
37. Ozyilmaz E, Ozturk OG, Durmaz A, Othman Hasan O, Guzelbaba B, Seydaoglu G, Kuleci S, Hanta I, Erken E, Kocabas A. Early prediction of sarcoidosis prognosis with HLA typing: a 5 year follow-up study. *Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG* 2018: 35(3): 184–191.
38. Belhomme N, Jouneau S, Bouzille G, Decaux O, Lederlin M, Guillot S, Perlat A, Jego P. Role of serum immunoglobulins for predicting sarcoidosis outcome: A cohort study. *PLoS One* 2018: 13(4): e0193122.
39. Chen H, Jin R, Wang Y, Li L, Li K, He Y. The Utility of (18)F-FDG PET/CT for Monitoring Response and Predicting Prognosis after Glucocorticoids Therapy for Sarcoidosis. *Biomed Res Int* 2018: 2018(1): 1823710.
40. Mañá J, Rubio-Rivas M, Villalba N, Marcoval J, Iriarte A, Molina-Molina M, Llatjos R, García O, Martínez-Yélamos S, Vicens-Zygmunt V, Gámez C, Pujol R, Corbella X. Multidisciplinary approach and long-term follow-up in a series of 640 consecutive patients with sarcoidosis: Cohort study of a 40-year clinical experience at a tertiary referral center in Barcelona, Spain. *Medicine* 2017: 96(29).
41. Maturu VN, Rayamajhi SJ, Agarwal R, Aggarwal AN, Gupta D, Mittal BR. Role of serial F-18 FDG PET/CT scans in assessing treatment response and predicting relapses in patients with symptomatic sarcoidosis. *Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG* 2016: 33(4): 372–380.
42. Liu Y, Qiu L, Wang Y, Aimurola H, Zhao Y, Li S, Xu Z. The Circulating Treg/Th17 Cell Ratio Is Correlated with Relapse and Treatment Response in Pulmonary Sarcoidosis Patients after Corticosteroid Withdrawal. *PLoS One* 2016: 11(2): e0148207.
43. Polverosi R, Russo R, Coran A, Battista A, Agostini C, Pomerri F, Giraudo C. Typical and atypical pattern of pulmonary sarcoidosis at high-resolution CT: relation to clinical evolution and therapeutic procedures. *Radiol Med* 2014: 119(6): 384–392.
44. Vorselaars AD, Verwoerd A, van Moorsel CH, Keijsers RG, Rijkers GT, Grutters JC. Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis. *The European respiratory journal* 2014: 43(2): 602–609.
45. Sharma SK, Balamurugan A, Pandey RM, Saha PK, Mehra NK. Human leukocyte antigen-DR alleles influence the clinical course of pulmonary sarcoidosis in Asian Indians. *Am J Respir Cell Mol Biol* 2003: 29(2): 225–231.
46. Kiper N, Anadol D, Ozcelik U, Gocmen A. Inhaled corticosteroids for maintenance treatment in childhood pulmonary sarcoidosis. *Acta paediatrica (Oslo, Norway : 1992)* 2001: 90(8): 953–956.
47. Sharma SK, Mohan A, Guleria JS. Clinical characteristics, pulmonary function abnormalities and outcome of prednisolone treatment in 106 patients with sarcoidosis. *The Journal of the Association of Physicians of India* 2001: 49: 697–704.
48. Baculard A, Blanc N, Boule M, Fauroux B, Chadelat K, Boccon-Gibod L, Tournier G, Clement A. Pulmonary sarcoidosis in children: a follow-up study. *The European respiratory journal* 2001: 17(4): 628–635.
49. Muller-Quernheim J, Kienast K, Held M, Pfeifer S, Costabel U. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. *The European respiratory journal* 1999: 14(5): 1117–1122.
50. Kim DS, Paik SH, Lim CM, Lee SD, Koh Y, Kim WS, Kim WD. Value of ICAM-1 expression and soluble ICAM-1 level as a marker of activity in sarcoidosis. *Chest* 1999: 115(4): 1059–1065.
51. Baltzan M, Mehta S, Kirkham TH, Cosio MG. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. *American journal of respiratory and critical care medicine* 1999: 160(1): 192–197.

52. Rizzato G, Montemurro L, Colombo P. The late follow-up of chronic sarcoid patients previously treated with corticosteroids. *Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG* 1998: 15(1): 52–58.
53. Wyser CP, van Schalkwyk EM, Alheit B, Bardin PG, Joubert JR. Treatment of progressive pulmonary sarcoidosis with cyclosporin A. A randomized controlled trial. *American journal of respiratory and critical care medicine* 1997: 156(5): 1371–1376.
54. Gottlieb JE, Israel HL, Steiner RM, Triolo J, Patrick H. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. *Chest* 1997: 111(3): 623–631.
55. Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. *Archives of internal medicine* 1995: 155(8): 846–851.
56. Takada K, Ina Y, Noda M, Sato T, Yamamoto M, Morishita M. The clinical course and prognosis of patients with severe, moderate or mild sarcoidosis. *Journal of clinical epidemiology* 1993: 46(4): 359–366.
57. Chadelat K, Baculard A, Grimfeld A, Tournier G, Boule M, Boccon-Gibod L, Clement A. Pulmonary sarcoidosis in children: serial evaluation of bronchoalveolar lavage cells during corticosteroid treatment. *Pediatr Pulmonol* 1993: 16(1): 41–47.
58. Prior C, Haslam PL. Increased levels of serum interferon-gamma in pulmonary sarcoidosis and relationship with response to corticosteroid therapy. *Am Rev Respir Dis* 1991: 143(1): 53–60.
59. Rizzato G, Fraioli P, Montemurro L. Long-term therapy with deflazacort in chronic sarcoidosis. *Chest* 1991: 99(2): 301–309.
60. Baumann MH, Strange C, Sahn SA. Do chest radiographic findings reflect the clinical course of patients with sarcoidosis during corticosteroid withdrawal? *AJR Am J Roentgenol* 1990: 154(3): 481–485.
61. Lower EE, Baughman RP. The use of low dose methotrexate in refractory sarcoidosis. *Am J Med Sci* 1990: 299(3): 153–157.
62. Johns CJ, Schonfeld SA, Scott PP, Zachary JB, MacGregor MI. Longitudinal study of chronic sarcoidosis with low-dose maintenance corticosteroid therapy. Outcome and complications. *Ann N Y Acad Sci* 1986: 465(1): 702–712.
63. Wallaert B, Ramon P, Fournier EC, Hatron PY, Muir JF, Tonnel AB, Voisin C. High-dose methylprednisolone pulse therapy in sarcoidosis. *European journal of respiratory diseases* 1986: 68(4): 256–262.
64. Turner-Warwick M, McAllister W, Lawrence R, Britten A, Haslam PL. Corticosteroid treatment in pulmonary sarcoidosis: do serial lavage lymphocyte counts, serum angiotensin converting enzyme measurements, and gallium-67 scans help management? *Thorax* 1986: 41(12): 903–913.
65. Eule H, Weinecke A, Roth I, Wuthe H. The possible influence of corticosteroid therapy on the natural course of pulmonary sarcoidosis. Late results of a continuing clinical study. *Ann N Y Acad Sci* 1986: 465(1): 695–701.
66. Johns CJ, Zachary JB, MacGregor MI, Curtis JL, Scott PP, Terry PB. The longitudinal study of chronic sarcoidosis. *Transactions of the American Clinical and Climatological Association* 1983: 94: 173–181.
67. Rohatgi PK, Ryan JW, Lindeman P. Value of serial measurement of serum angiotensin converting enzyme in the management of sarcoidosis. *The American journal of medicine* 1981: 70(1): 44–50.
68. Johns CJ, Macgregor MI, Zachary JB, Ball WC. Extended experience in the long-term corticosteroid treatment of pulmonary sarcoidosis. *Ann N Y Acad Sci* 1976: 278(1): 722–731.
69. Johns CJ, Zachary JB, Ball WC, Jr. A ten-year study of corticosteroid treatment of pulmonary sarcoidosis. *The Johns Hopkins medical journal* 1974: 134(5): 271–283.
70. Emirgil C, Sobol BJ, Williams MH, Jr. Long-term study of pulmonary sarcoidosis. The effect of steroid therapy as evaluated by pulmonary function studies. *J Chronic Dis* 1969: 22(2): 69–86.
71. Morse SI, Cohn ZA, Hirsch JG, Schaeder RW. The treatment of sarcoidosis with chloroquine. *The American journal of medicine* 1961: 30: 779–784.
72. Nagai S, Handa T, Ito Y, Ohta K, Tamaya M, Izumi T. Outcome of sarcoidosis. *Clinics in chest medicine* 2008: 29(3): 565–574, x.

73. Crouser ED, Maier LA, Wilson KC, Bonham CA, Morgenthau AS, Patterson KC, Abston E, Bernstein RC, Blankstein R, Chen ES, Culver DA, Drake W, Drent M, Gerke AK, Ghobrial M, Govender P, Hamzeh N, James WE, Judson MA, Kellermeyer L, Knight S, Koth LL, Poletti V, Raman SV, Tukey MH, Westney GE, Baughman RP. Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. *American journal of respiratory and critical care medicine* 2020: 201(8): e26–e51.
74. Scadding JG. Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years' observation. *British medical journal* 1961: 2(5261): 1165–1172.
75. Desai SR, Sivarasan N, Johannson KA, George PM, Culver DA, Devaraj A, Lynch DA, Milne D, Renzoni E, Nunes H, Sverzellati N, Spagnolo P, Baughman RP, Yadav R, Piciucchi S, Walsh SLF, Kouranos V, Wells AU. High-resolution CT phenotypes in pulmonary sarcoidosis: a multinational Delphi consensus study. *Lancet Respir Med* 2024: 12(5): 409–418.
76. Belperio JA, Fishbein MC, Abtin F, Channick J, Balasubramanian SA, Lynch Iii JP. Pulmonary sarcoidosis: A comprehensive review: Past to present. *Journal of autoimmunity* 2023: 103107.
77. Wijsenbeek MS, Culver DA. Treatment of Sarcoidosis. *Clinics in chest medicine* 2015: 36(4): 751–767.
78. Sangani R, Bosch NA, Govender P, Scarpato B, Walkey AJ, Newman J, Law AC, Gillmeyer KR, Shankar DA. Sarcoidosis Treatment Patterns in the United States: 2016-2022. *Chest* 2025: 167(4): 1099–1106.
79. Sarcoidosis So. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. *American journal of respiratory and critical care medicine* 1999: 160(2): 736–755.
80. Kahlmann V, Moor CC, Miedema JR, Wijsenbeek MS. Comparison of the treatment guidelines for sarcoidosis: common sense in the search for evidence. *European Respiratory Journal* 2022: 59(2): 2103114.
81. Akram MJ, Khalid U, Abu Bakar M, Butt FM, Ashraf MB. Sarcoidosis: epidemiology, characteristics, and outcomes over 10 years - a single-center study in Pakistan. *Expert review of respiratory medicine* 2022: 16(1): 133–143.
82. Vis R, Mathijssen H, Keijsers RGM, van de Garde EMW, Veltkamp M, Akdim F, Post MC, Grutters JC. Prednisone vs methotrexate in treatment naive cardiac sarcoidosis. *Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology* 2023: 30(4): 1543–1553.
83. Kahlmann V, Janssen Bonás M, Moor CC, Grutters JC, Mostard RLM, van Rijswijk H, van der Maten J, Marges ER, Moonen LAA, Overbeek MJ, Koopman B, Loth DW, Nossent EJ, Wagenaar M, Kramer H, Wielders P, Bonta PI, Walen S, Bogaarts B, Kerstens R, Overgaauw M, Veltkamp M, Wijsenbeek MS. First-Line Treatment of Pulmonary Sarcoidosis with Prednisone or Methotrexate. *N Engl J Med* 2025: 393(3): 231–242.
84. Ballul T, Borie R, Crestani B, Daugas E, Descamps V, Dieude P, Dossier A, Extramiana F, van Gysel D, Papo T, Sacre K. Treatment of cardiac sarcoidosis: A comparative study of steroids and steroids plus immunosuppressive drugs. *International journal of cardiology* 2019: 276: 208–211.
85. Nagai S, Yokomatsu T, Tanizawa K, Ikezoe K, Handa T, Ito Y, Ogino S, Izumi T. Treatment with methotrexate and low-dose corticosteroids in sarcoidosis patients with cardiac lesions. *Internal medicine (Tokyo, Japan)* 2014: 53(5): 427–433.
86. Baughman RP, Lower EE. A clinical approach to the use of methotrexate for sarcoidosis. *Thorax* 1999: 54(8): 742–746.
87. Schutt AC, Bullington WM, Judson MA. Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study. *Respir Med* 2010: 104(5): 717–723.
88. Culver DA, Aryal S, Barney J, Hsia CCW, James WE, Maier LA, Marts LT, Obi ON, Sporn PHS, Sweiss NJ, Shukla S, Kinnersley N, Walker G, Baughman R. Efzofitimod for the Treatment of Pulmonary Sarcoidosis. *Chest* 2023: 163(4): 881–890.
89. Redl A, Doberer K, Unterluggauer L, Kleissl L, Krall C, Mayerhofer C, Reininger B, Stary V, Zila N, Weninger W, Weichhart T, Bock C, Krausgruber T, Stary G. Efficacy and safety of mTOR inhibition in cutaneous sarcoidosis: a single-centre trial. *Lancet Rheumatol* 2024: 6(2): e81–e91.

90. Burke RR, Stone CH, Havstad S, Rybicki BA. Racial differences in sarcoidosis granuloma density. *Lung* 2009: 187(1): 1–7.
91. Hena KM. Sarcoidosis Epidemiology: Race Matters. *Front Immunol* 2020: 11: 537382.
92. Mirsaeidi M, Machado RF, Schraufnagel D, Sweiss NJ, Baughman RP. Racial difference in sarcoidosis mortality in the United States. *Chest* 2015: 147(2): 438–449.
93. da Costa CH, Silva VL, Fabricio-Silva GM, Usnayo M, Rufino R, Porto LC. HLA in a cohort of Brazilian patients with sarcoidosis. *Hum Immunol* 2013: 74(10): 1326–1332.
94. Harman NL, Gorst SL, Williamson PR, Barnathan ES, Baughman RP, Judson MA, Junk H, Kampstra NA, Sullivan EJ, Victorson DE, Walton M, Al-Hakim T, Nabulsi H, Singh N, Grutters JC, Culver DA. Scout - sarcoidosis outcomes taskforce. A systematic review of outcomes to inform the development of a core outcome set for pulmonary sarcoidosis. *Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG* 2021: 38(3): e2021034.
95. Baughman RP, Judson MA, Beaumont JL, Maier LA, Sweiss NJ, Culver DA, Chen ES, Singh N, Lower EE, Reeves R, Hamzeh N, Grutters JC, Valeyre D, Birring SS. Evaluating the Minimal Clinically Important Difference of the King's Sarcoidosis Questionnaire in a Multicenter Prospective Study. *Ann Am Thorac Soc* 2021: 18(3): 477–485.

Study No	Study (Year)	Frame	Method	Size	Description	Coverage	Validity	Reliability	Analysis	Response	Bias	Score	Risk
1	Bouchut et al. (2024)	Low	High	Low	Low	Low	Low	Low	Low	Low	Low	9	Low
2	Guliyeva et al. (2024)	Low	High	Low	Low	Low	Low	Low	Low	Low	Low	9	Low
3	Dhooria et al. (2023)	Low	Low	Low	Low	Low	Low	Low	Low	Low	Low	10	Low
4	Ozdemirel et al. (2023)	Low	High	Low	Low	Low	High	High	Low	Low	Low	7	Moderate
5	Spyropoulos et al. (2022)	Low	Low	Low	Low	Low	High	Low	Low	Low	Low	9	Low
6	Madan et al. (2022)	Low	Low	Low	Low	Low	Low	Low	Low	Low	Low	10	Low
7	Sakkat et al. (2022)	Low	High	High	High	Low	High	Low	Low	Low	Low	6	Moderate
8	Morar et al. (2022)	Low	High	Low	Low	Low	High	Low	Low	Low	Low	8	Low
9	Feng et al. (2022)	Low	High	Low	Low	Low	Low	Low	Low	Low	Low	9	Low
10	Gavrysyuk et al. (2021)	Low	Low	Low	Low	Low	Low	Low	Low	Low	Low	10	Low
11	Murata et al. (2021)	Low	High	Low	Low	Low	Low	Low	Low	Low	Low	9	Low
12	Gavrysyuk et al. (2021)	Low	Low	Low	Low	Low	Low	Low	Low	Low	Low	10	Low
13	Fang et al. (2019)	Low	High	High	Low	Low	Low	Low	Low	Low	Low	8	Low
14	Nath et al. (2019)	Low	High	Low	Low	Low	Low	Low	Low	Low	Low	9	Low
15	Zheng et al. (2019)	Low	High	Low	High	Low	Low	Low	Low	Low	Low	8	Low
16	Ozyilmaz et al. (2018)	Low	Low	High	High	Low	High	Low	Low	Low	Low	7	Moderate
17	Belhomme et al. (2018)	Low	High	High	High	Low	Low	Low	Low	Low	Low	7	Moderate
18	Chen et al. (2018)	Low	High	High	Low	Low	Low	Low	Low	Low	Low	8	Low
19	Mañá et al. (2017)	Low	Low	Low	High	Low	Low	Low	Low	Low	Low	9	Low
20	Maturu et al. (2016)	Low	Low	High	Low	Low	Low	Low	Low	Low	Low	9	Low
21	Liu et al. (2016)	Low	Low	High	Low	Low	Low	Low	Low	Low	Low	9	Low
22	Polverosi et al. (2014)	Low	High	High	Low	Low	High	Low	Low	Low	Low	7	Moderate
23	Vorselaars et al. (2014)	Low	High	High	Low	Low	Low	Low	Low	Low	Low	8	Low
24	Sharma et al. (2003)	Low	High	Low	Low	Low	High	Low	Low	Low	Low	8	Low
25	Kiper et al. (2001)	Low	High	High	Low	Low	Low	Low	Low	Low	Low	8	Low
26	Sharma et al. (2001)	Low	Low	Low	Low	Low	Low	Low	Low	Low	Low	10	Low
27	Baculard et al. (2001)	Low	High	High	Low	Low	Low	Low	Low	Low	Low	8	Low
28	Muller-Quernheim et al. (1999)	Low	Low	High	Low	Low	High	Low	Low	Low	Low	8	Low
29	Kim et al. (1999)	Low	Low	High	Low	Low	High	High	Low	Low	Low	7	Moderate
30	Baltzan et al. (1999)	Low	Low	High	Low	Low	Low	Low	Low	Low	Low	9	Low
31	Rizzato et al. (1998)	Low	High	Low	High	Low	High	Low	Low	Low	Low	7	Moderate
32	Wyser et al. (1997)	Low	Low	High	High	Low	Low	Low	Low	Low	Low	8	Low
33	Gottlieb et al. (1997)	Low	Low	Low	High	Low	Low	Low	Low	Low	Low	9	Low
34	Lower et al. (1995)	Low	High	High	High	Low	Low	Low	Low	Low	Low	7	Moderate
35	Takada et al. (1993)	Low	High	Low	High	Low	High	Low	Low	Low	Low	7	Moderate
36	Chadelat et al. (1993)	Low	Low	High	Low	Low	High	Low	Low	Low	Low	8	Low
37	Prior et al. (1991)	Low	Low	High	Low	Low	High	Low	Low	Low	Low	8	Low
38	Rizzato et al. (1991)	Low	High	High	Low	Low	High	Low	Low	Low	Low	7	Moderate
39	Baumann et al. (1990)	Low	High	High	Low	Low	High	Low	Low	Low	Low	7	Moderate
40	Lower et al. (1990)	Low	High	High	Low	Low	High	Low	Low	Low	Low	7	Moderate
41	Johns et al. (1986)	Low	High	Low	Low	Low	High	High	Low	Low	Low	7	Moderate
42	Wallaert et al. (1986)	Low	Low	High	Low	Low	High	High	Low	Low	Low	7	Moderate
43	Turner-Warwick et al. (1986)	Low	Low	High	Low	Low	High	High	Low	Low	Low	7	Moderate
44	Eule et al. (1986)	Low	Low	Low	High	Low	High	Low	Low	Low	Low	8	Low
45	Johns et al. (1983)	Low	High	Low	Low	Low	High	Low	Low	Low	Low	8	Low
46	Rohatgi et al. (1981)	Low	Low	High	High	Low	High	Low	Low	Low	Low	7	Moderate
47	Johns et al. (1976)	Low	High	Low	High	Low	High	Low	Low	Low	Low	7	Moderate
48	Johns et al. (1974)	Low	High	Low	Low	Low	High	Low	Low	Low	Low	8	Low
49	Emirgil et al. (1969)	Low	High	High	High	Low	High	Low	Low	Low	Low	6	Moderate
50	Morse et al. (1961)	Low	High	High	Low	Low	High	Low	Low	Low	Low	7	Moderate

Table 2: Quality assessment of studies using the Hey et al. (2012) risk of bias tool. Columns: Study No (study identifier), Study (Year) (author, publication year), Frame (sampling frame quality), Method (study methodology rigor), Size (sample size adequacy), Description (clarity of study description), Coverage (population coverage), Validity (measurement validity), Reliability (measurement reliability), Analysis (analytical rigor), Response (response rate quality), Bias (potential bias), Score (overall quality score), Risk (risk of bias: Low, Moderate).



Fig. 1

Figure 1: PRISMA flow diagram depicting the study selection process, including identification, screening, eligibility assessment, and inclusion of eligible studies.

Figure 2: Significant forest plots from meta-analysis on overall relapse prevalence, black race and prospective studies



(a)



(b)



(c)

Forest plot (a) depicting the pooled proportion of relapse with 95% CI across individual studies.

Forest plot log odds ratio of relapse with 95% CI comparing (b) Black and White populations. (c) prospective studies

Figure 3: Forest plots for stage, isolated vs multiorgan involvement and treatment



(a) (b) (c)

Forest plot showing pooled log odd ratios of the prevalence of relapse in pulmonary sarcoidosis patients for: Top: radiographic Stage IV vs Stage I Middle: Stage II & III vs Stage I Lower: Stage II & III combined vs Stage IV

Forest plots showing pooled proportions of relapses in patients with isolated single-organ pulmonary sarcoidosis and patients with multiorgan systemic pulmonary sarcoidosis.

Forest plot showing the pooled proportions of relapses in pulmonary sarcoidosis patients receiving steroids, steroid-sparing agents and mixed treatment (steroid+steroid-sparing agents)



Figure 4: ***Sensitivity anlaysis:*** Forest plot showing the proportion of studies with 95% CI across subgroups: design (prospective vs. retrospective), relapse definition (yes vs. no), year (after vs. before 2000), Asian vs. Non-Asian, patients >50 (yes vs. no), and quality (low vs. moderate risk of bias).



(a)

Baujat plot: Study numbers 34, 48, 41, 45, and 24 identified as outliers and overtly influential



(b)

Galbraith plot shows the relationship between study precision (1/se) and standardized effect size (θ/se %), with labeled studies, a regression line, a 95% CI band, and a no-effect line to assess heterogeneity and identify outliers.



(c)

Symmetrical funnel plot depicting no visual publication bias. The numbers adjacent to the marker depict the study numbers given in Table 1.

Figure 5: Diagnostic plots for investigating heterogeneity and publication bias in meta-analysis



(a)

Pie chart showing different types of relapses observed in patients



(b)

Box plots showing the distribution of median times to relapse, with the left plot depicting the minimum median time (3 months, range 1–12 months) and the right plot depicting the maximum median time (13 months, range 2–60 months), including interquartile ranges.

Figure 6: Types of relapses, time to relapse, potential trajectories of sarcoidosis's natural disease history



Line graphs showing trajectories of pulmonary sarcoidosis evolution, including (A) disease progression, (B) disease exacerbation, and (D) disease relapse.

Supplementary Tables and Analysis

Search Terms:

PubMed: (("Sarcoidosis, Pulmonary"[Mesh] OR "pulmonary sarcoidosis"[Title/Abstract] OR "lung sarcoidosis"[Title/Abstract] OR "sarcoidosis"[Title/Abstract]) AND ("Recurrence"[Mesh] OR "relapse"[Title/Abstract] OR "recurrence"[Title/Abstract] OR "flare-up"[Title/Abstract] OR "exacerbation"[Title/Abstract]) AND ("Prevalence"[Mesh] OR "prevalence"[Title/Abstract] OR "incidence"[Title/Abstract] OR "frequency"[Title/Abstract] OR "rate"[Title/Abstract] OR "Risk Factors"[Mesh] OR "risk factors"[Title/Abstract] OR "predictors"[Title/Abstract] OR "associations"[Title/Abstract] OR "determinants"[Title/Abstract])).

For Scopus:

TITLE-ABS-KEY (("pulmonary sarcoidosis" OR "lung sarcoidosis" OR "sarcoidosis") AND ("relapse" OR "recurrence" OR "flareup" OR "exacerbation") AND ("prevalence" OR "incidence" OR "frequency" OR "rate" OR "risk factors" OR "predictors" OR "associations" OR "determinants")) OR INDEXTERMS ("Sarcoidosis, Pulmonary" OR "Recurrence" OR "Prevalence" OR "Risk Factors")

For Embase:

('lung sarcoidosis'/exp OR 'pulmonary sarcoidosis':ti,ab,kw OR 'lung sarcoidosis':ti,ab,kw OR 'sarcoidosis':ti,ab,kw) AND ('disease recurrence'/exp OR 'relapse':ti,ab,kw OR 'recurrence':ti,ab,kw OR 'flareup':ti,ab,kw OR 'exacerbation':ti,ab,kw) AND ('prevalence'/exp OR 'prevalence':ti,ab,kw OR 'incidence':ti,ab,kw OR 'frequency':ti,ab,kw OR 'rate':ti,ab,kw OR 'risk factor'/exp OR 'risk factors':ti,ab,kw OR 'predictors':ti,ab,kw OR 'associations':ti,ab,kw OR 'determinants':ti,ab,kw)

Google Scholar:

("pulmonary sarcoidosis" OR "lung sarcoidosis" OR sarcoidosis) AND (relapse OR recurrence OR "flare up" OR "flare-up" OR flareup OR exacerbation) AND (prevalence OR incidence OR frequency OR rate OR "risk factors" OR predictors OR associations OR determinants)

Supplementary Table 1: Sarcoidosis Relapse Definitions

Study No	Study (Year)	Definition
1	Bouchut et al. (2024)	Radiological changes (e.g., new nodules or lymphadenopathy on CT) or biological markers (e.g., elevated serum ACE levels) indicating disease recurrence, necessitating treatment.
2	Guliyeva et al. (2024)	Recurrence of clinical symptoms (e.g., cough, dyspnea) or signs post-remission, after at least 6 months of absent inflammatory activity, with or without ongoing treatment.
3	Dhooria et al. (2023)	Worsening of clinical symptoms (e.g., dyspnea, fatigue), pulmonary function tests (e.g., reduced FEV1 or FVC), or radiological findings (e.g., new infiltrates on chest imaging).
8	Morar et al. (2022)	Recurrence of sarcoidosis symptoms or signs (e.g., respiratory or systemic manifestations) during tapering or discontinuation of anti-sarcoidosis medications, such as corticosteroids.
9	Feng et al. (2022)	Recurrence of sarcoidosis symptoms or signs (e.g., cough, shortness of breath, or radiological changes) after complete disease control, indicating relapse.
10	Gavrysyuk et al. (2021)	Worsening of clinical symptoms (e.g., dyspnea, cough) and/or radiological findings (e.g., new lymphadenopathy or infiltrates on CT) post-normalization, requiring retreatment.
11	Murata et al. (2021)	Reappearance of symptoms (e.g., dyspnea, dry cough) or radiological signs (e.g., bilateral hilar lymphadenopathy or parenchymal infiltration on chest X-ray/CT) post-remission, or sudden worsening of stable disease.
12	Gavrysyuk et al. (2021)	Appearance of new sarcoidosis areas on CT (e.g., pulmonary infiltrates) with or without worsening clinical symptoms (e.g., cough), necessitating retreatment.

Study No	Study (Year)	Definition
13	Fang et al. (2019)	New pulmonary sarcoidosis symptoms (e.g., cough, shortness of breath) or exacerbation of existing symptoms, confirmed by clinical or radiological assessment.
14	Nath et al. (2019)	Worsening of clinical symptoms (e.g., respiratory distress), radiological findings (e.g., new nodules on CT), or biological markers (e.g., elevated serum ACE or inflammatory markers).
15	Zheng et al. (2019)	A chest HRCT showing radiographic progression in combination of worsening of clinical symptoms to warrant retreatment following a decrease in dose or discontinuation of corticosteroids, without alternative causes such as infections, heart failure, or pulmonary embolism.
17	Belhomme et al. (2018)	Progressive disease requiring escalation of corticosteroid therapy (e.g., increased dose) or resumption of corticosteroids after cessation, due to worsening symptoms or imaging findings.
18	Chen et al. (2018)	Progression of clinical symptoms (e.g., increased cough or dyspnea) and/or radiological changes (e.g., new lesions on imaging) post-clinical and radiological normalization.
19	Mañá et al. (2017)	The reappearance of former signs or symptoms associated with pulmonary sarcoidosis after remission, such as BHL or parenchymal infiltration on chest X-rays or chest CT scans, or appearance of dyspnea or dry cough; “exacerbation” was the sudden worsening of stable disease, such as BHL, parenchymal infiltration or fibrosis on chest X-rays or chest CT scans, or increased frequency of dyspnea or dry cough; “improved,” was amelioration of signs or symptoms associated with pulmonary sarcoidosis; and “stable,” was neither “relapse,” “exacerbation” nor “improved.”
20	Maturu et al. (2016)	Worsening of pulmonary or extrapulmonary symptoms (e.g., dyspnea, skin lesions) and/or radiological progression (e.g., new infiltrates) without alternative causes, requiring reintroduction of steroids or steroid-sparing agents.

Study No	Study (Year)	Definition
25	Kiper et al. (2001)	Presence of more than two of these criteria: Worsening of radiological findings and pulmonary function tests, occurrence of hepatosplenomegaly, new eye involvement, elevation of serum globulins, alkaline phosphatase and serum ACE, hypercalcemia and hypercalciuria..
27	Baculard et al. (2001)	Return of respiratory symptoms (e.g., cough, shortness of breath) after normalization of radiological findings and pulmonary function tests (e.g., normal FEV1, FVC).
30	Baltzan et al. (1999)	A decline in lung function from time 0 (the beginning of run in) in any value of FEV1, FVC, or DLCO-SB of 15% or more for two consecutive measurements. Radiography alone was not used to define relapse.
32	Wyser et al. (1997)	Clinical deterioration (e.g., worsening respiratory symptoms) at least 3 months after treatment cessation, or failure after ≥ 9 months of treatment, requiring intervention.
33	Gottlieb et al. (1997)	Return of severe clinical symptoms (e.g., dyspnea, fatigue) warranting treatment, after > 1 month of symptom-free remission without corticosteroids.
34	Lower et al. (1995)	Increased sarcoidosis symptoms (e.g., cough, shortness of breath) or worsening pulmonary function test results (e.g., reduced FEV1 or DLCO).

ACE: Angiotensin-Converting Enzyme, BHL: Bilateral Hilar Lymphadenopathy, CS: Corticosteroids, CT: Computed Tomography, DLCO: Diffusing Capacity of the Lung for Carbon Monoxide, DLCO-SB: Diffusing Capacity of the Lung for Carbon Monoxide – Single Breath, FEV1: Forced Expiratory Volume in One Second, FVC: Forced Vital Capacity, HRCT: High-Resolution Computed Tomography.

Supplementary Table 2: Meta-regression

Variable	Coefficient	p-value	Standard error	z
Relapse definition	-0.021(-0.17, 0.12)	0.78	0.074	-0.28
Year of publication	0.095(-0.06, 0.25)	0.228	0.079	1.21
Design of study	**0.144(0.02, 0.27)**	**0.026***	**0.065**	**2.22**
Asian vs Others	0.072(-0.07, 0.21)	0.305	0.070	1.03
Sample size > 50	-0.04(-0.18, 0.1)	0.571	0.070	-0.57
Quality of studies	-0.034(-0.2, 0.13)	0.689	0.084	-0.4
Adult	-0.031(-0.26, 0.2)	0.791	0.118	-0.27

Only significant factor was design of study

Supplementary Table 3: Freeman-Tukey arcsine transformation

Study number	Study	ES	CI (Low)	CI (Low)	Weight (%)
1	Bouchut et al. (2024)	0.53	0.45	0.6	2.18
2	Guliyeva et al. (2024)	0.27	0.17	0.4	2.09
3	Dhooria et al. (2023)	0.45	0.35	0.56	2.12
4	Ozdemirel et al. (2023)	0.22	0.14	0.33	2.15
5	Spyropoulos et al. (2022)	0.29	0.22	0.36	2.18
6	Madan et al. (2022)	0.22	0.18	0.27	2.22
7	Sakkat et al. (2022)	0.64	0.35	0.85	1.59
8	Morar et al. (2022)	0.61	0.5	0.7	2.13
9	Feng et al. (2022)	0.2	0.13	0.27	2.19
10	Gavrysyuk et al. (2021)	0.33	0.24	0.44	2.13
11	Murata et al. (2021)	0.22	0.15	0.31	2.17
12	Gavrysyuk et al. (2021)	0.52	0.43	0.61	2.15
13	Fang et al. (2019)	0.18	0.05	0.48	1.77
14	Nath et al. (2019)	0.24	0.17	0.33	2.18
15	Zheng et al. (2019)	0.31	0.23	0.41	2.15
16	Ozyilmaz et al. (2018)	0.45	0.28	0.62	1.92
17	Belhomme et al. (2018)	0.29	0.17	0.46	2
18	Chen et al. (2018)	0.52	0.33	0.71	1.85

19	Mañá et al. (2017)	0.11	0.08	0.16	2.23
20	Maturu et al. (2016)	0.37	0.22	0.56	1.92
21	Liu et al. (2016)	0.48	0.33	0.62	2.01
22	Polverosi et al. (2014)	0.2	0.11	0.35	2.09
23	Vorselaars et al. (2014)	0.62	0.47	0.74	2.04
24	Sharma et al. (2003)	0.75	0.62	0.85	2.1
25	Kiper et al. (2001)	0.4	0.2	0.64	1.71
26	Sharma et al. (2001)	0.25	0.17	0.35	2.15
27	Baculard et al. (2001)	0.19	0.08	0.4	1.96
28	Muller-Quernheim et al. (1999)	0.27	0.1	0.57	1.66
29	Kim et al. (1999)	0.15	0.06	0.32	2.06
30	Baltzan et al. (1999)	0.44	0.25	0.66	1.77
31	Rizzato et al. (1998)	0.37	0.27	0.47	2.13
32	Wyser et al. (1997)	0.44	0.23	0.67	1.72
33	Gottlieb et al. (1997)	0.39	0.33	0.45	2.2
34	Lower et al. (1995)	0.88	0.74	0.95	2.13
35	Takada et al. (1993)	0.47	0.37	0.58	2.11
36	Chadelat et al. (1993)	0.25	0.07	0.59	1.54
37	Prior et al. (1991)	0.24	0.11	0.43	1.96
38	Rizzato et al. (1991)	0.1	0.04	0.23	2.15
39	Baumann et al. (1990)	0.67	0.42	0.85	1.74
40	Lower et al. (1990)	0.36	0.16	0.61	1.7
41	Johns et al. (1986)	0.75	0.68	0.81	2.2
42	Wallaert et al. (1986)	0.67	0.39	0.86	1.65
43	Turner-Warwick et al. (1986)	0.12	0.05	0.28	2.1
44	Eule et al. (1986)	0.22	0.15	0.3	2.18
45	Johns et al. (1983)	0.75	0.65	0.82	2.16
46	Rohatgi et al. (1981)	0.3	0.15	0.52	1.86
47	Johns et al. (1976)	0.7	0.62	0.77	2.18
48	Johns et al. (1974)	0.78	0.71	0.84	2.19
49	Emirgil et al. (1969)	0.27	0.13	0.48	1.91
50	Morse et al. (1961)	0.57	0.25	0.84	1.33
	Random pooled ES	**0.40**	**0.33**	**0.46**	**100**

Sensitivity analysis using the Freeman–Tukey double arcsine transformation for relapse proportions across 50 studies shows a random pooled effect size (ES) of 0.40 (95% CI: 0.33 to 0.46)

Supplementary Table 4: Sensitivity analysis using **Leave-one-out**

Omitted study number	Proportion	95% CI lower	95% CI upper
1	0.395	0.335	0.454
2	0.401	0.341	0.46
3	0.397	0.337	0.456
4	0.402	0.342	0.461
5	0.4	0.341	0.46
6	0.402	0.342	0.461
7	0.394	0.335	0.453
8	0.393	0.334	0.452
9	0.402	0.343	0.462
10	0.399	0.339	0.459
11	0.402	0.342	0.461
12	0.395	0.335	0.455
13	0.402	0.342	0.461
14	0.401	0.342	0.461
15	0.4	0.34	0.459
16	0.397	0.337	0.456
17	0.4	0.34	0.46
18	0.395	0.336	0.455
19	0.404	0.346	0.463
20	0.398	0.339	0.458
21	0.396	0.336	0.456
22	0.402	0.343	0.461
23	0.393	0.334	0.452
24	**0.39**	**0.332**	**0.448**
25	0.398	0.338	0.457
26	0.401	0.342	0.461
27	0.402	0.343	0.461
28	0.4	0.34	0.459
29	0.403	0.344	0.462
30	0.397	0.337	0.457
31	0.398	0.339	0.458
32	0.397	0.338	0.457
33	0.398	0.338	0.458
34	**0.387**	**0.331**	**0.443**
35	0.396	0.336	0.456
36	0.4	0.341	0.459
37	0.401	0.341	0.46
38	0.404	0.346	0.463
39	0.393	0.334	0.452
40	0.398	0.339	0.458

41	**0.39**	**0.332**	**0.447**
42	0.393	0.335	0.452
43	0.404	0.345	0.462
44	0.402	0.342	0.461
45	**0.39**	**0.332**	**0.448**
46	0.4	0.34	0.459
47	0.391	0.332	0.449
48	0.389	0.331	0.446
49	0.4	0.341	0.46
50	0.396	0.336	0.455
Overall	**0.398**	**0.339**	**0.456**

Supplementary Table 4: Data for Galbraith plot

Study No	Study	x (Precision: 1/SE)	y (Standardized Deviation)	Outlier (>2 SD)	Outlier> 3 SD
1	Bouchut et al. (2024)[22]	6.57	3.26	1	1
2	Guliyeva et al. (2024)[23]	3.2	-1.94	2	2
3	Dhooria et al. (2023)[24]	4.62	0.95	2	2
4	Ozdemirel et al. (2023)[25]	3.53	-3.1	1	1
5	Spyropoulos et al. (2022)[26]	5.48	-2.87	1	2
6	Madan et al. (2022)[27]	7.53	-6.43	1	1
7	Sakkat et al. (2022)[28]	1.6	1.52	2	2
8	Morar et al. (2022)[29]	4.61	3.81	1	1
9	Feng et al. (2022)[30]	4.4	-4.5	1	1
10	Gavrysyuk et al. (2021a)[31]	4.32	-1.3	2	2
11	Murata et al. (2021)[32, 33]	4.23	-3.61	1	1
12	Gavrysyuk et al. (2021b)[33]	5.19	2.42	1	2
13	Fang et al. (2019)[34]	1.28	-1.42	2	2
14	Nath et al. (2019)[35]	4.69	-3.52	1	1
15	Zheng et al. (2019)[36]	4.54	-1.8	2	2
16	Ozyilmaz et al. (2018)[37]	2.68	0.49	2	2

17	Belhomme et al. (2018)[38]	2.66	-1.28	2	2
18	Chen et al. (2018)[39]	2.4	1.15	2	2
19	MaÃ±Ã¡ et al. (2017)[40]	5.16	-8.62	1	1
20	Maturu et al. (2016)[41]	2.51	-0.35	2	2
21	Liu et al. (2016)[42]	3.24	0.96	2	2
22	Polverosi et al. (2014)[43]	2.68	-2.58	1	2
23	Vorselaars et al. (2014)[44]	3.33	2.9	1	2
24	Sharma et al. (2003)[45]	3.13	4.75	1	1
25	Kiper et al. (2001)[46]	1.9	-0.02	2	2
26	Sharma et al. (2001)[47]	3.98	-2.87	1	2
27	Baculard et al. (2001)[48]	1.8	-1.9	2	2
28	Muller-Quernheim et al. (1999)[49]	1.48	-0.87	2	2
29	Kim et al. (1999)[50]	1.85	-2.5	1	2
30	Baltzan et al. (1999)[51]	2.11	0.36	2	2
31	Rizzato et al. (1998)[52]	4.36	-0.69	2	2
32	Wyser et al. (1997)[53]	1.98	0.28	2	2
33	Gottlieb et al. (1997)[54]	7.25	-0.42	2	2
34	Lower et al. (1995)[55]	2.09	4.89	1	1
35	Takada et al. (1993)[56]	4.35	1.25	2	2
36	Chadelat et al. (1993)[57]	1.22	-0.87	2	2
37	Prior et al. (1991)[58]	2.14	-1.62	2	2
38	Rizzato et al. (1991)[59]	1.9	-3.42	1	1
39	Baumann et al. (1990)[60]	1.83	1.98	2	2
40	Lower et al. (1990)[61]	1.79	-0.35	2	2
41	Johns et al. (1986)[62]	5.67	8.41	1	1
42	Wallaert et al. (1986)[63]	1.63	1.77	2	2
43	Turner-Warwick et al. (1986)[64]	1.87	-2.91	1	2
44	Eule et al. (1986)[65]	4.33	-3.83	1	1
45	Johns et al. (1983)[66]	4.32	6.39	1	1
46	Rohatgi et al. (1981)[67]	2.05	-0.93	2	2
47	Johns et al. (1976)[68]	5.54	6.84	1	1
48	Johns et al. (1974)[69]	4.99	8.26	1	1
49	Emirgil et al. (1969)[70]	2.09	-1.23	2	2
50	Morse et al. (1961)[71]	1.31	0.89	2	2

A statistical note on deeper heterogeneity assessment: Because significant heterogeneity was detected, a prediction interval for the true outcomes is also provided [1]. Studentized residuals and Cook's distances are used to examine whether studies may be outliers and/or influential in the context of the model [2]. Studies with a studentized residual larger than the $100 \times \left(1 - 0.05/(2 \times k)\right)$th percentile of standard normal distribution were considered potential outliers

(i.e., using a Bonferroni correction with two-sided $\alpha = 0.05$ for k studies included in the meta-analysis). Studies with a Cook's distance larger than the ***median plus six times the interquartile range of the Cook's distances*** are considered to be influential.

A 95% prediction interval for the true outcomes is given by 0.0080 to 0.7875. Hence, even though there may be some heterogeneity, the true outcomes of the studies are generally in the same direction as the estimated average outcome.

Supplementary Table 5: GRADE assessment

Outcome	Studies (N)	Certainty	Reasons for Rating
Relapse Prevalence	50 (3646 patients)	Low	Downgraded for bias and inconsistency
Relapse Prevalence (Prospective Studies)	21 (subset of 3646 patients)	Moderate	Downgraded for bias and inconsistency
Risk by Black Race	Subset with data	Moderate	Downgraded for bias; upgraded for large effect

List of studies which were rejected:[3-31]

1. Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. BMJ (Clinical research ed) 2011;342:d549. doi:10.1136/bmj.d549

2. Viechtbauer W. Bias and Efficiency of Meta-Analytic Variance Estimators in the Random-Effects Model. Journal of Educational and Behavioral Statistics 2005;30(3):261–93. doi:10.3102/10769986030003261

3. Izzat MB, Kabbani SS, Suma H, Pandey K, Morishita K, Yim AP. Early experience with partial left ventriculectomy in the Asia-Pacific region. Ann Thorac Surg 1999;

4. Coppo P, Bengoufa D, Veyradier A, Wolf M, Bussel A, Millot GA*, et al*. Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine (Baltimore) 2004;

5. Calabrese LH, Kirchner E, Shrestha R. Rheumatic complications of human immunodeficiency virus infection in the era of highly active antiretroviral therapy: emergence of a new syndrome of immune reconstitution and changing patterns of disease. Semin Arthritis Rheum 2005;
6. Quaden C, Tillie-Leblond I, Delobbe A, Delaunois L, Verstraeten A, Demedts M*, et al*. Necrotising sarcoid granulomatosis: clinical, functional, endoscopical and radiographical evaluations. Eur Respir J 2005;
7. Aouizerate J, Matignon M, Kamar N, Thervet E, Randoux C, Moulin B*, et al*. Renal transplantation in patients with sarcoidosis: a French multicenter study. Clin J Am Soc Nephrol 2010;
8. Crawford T, Mueller G, Sarsam S, Prasitdumrong H, Chaiyen N, Gu X*, et al*. Magnetic resonance imaging for identifying patients with cardiac sarcoidosis and preserved or mildly reduced left ventricular function at risk of ventricular arrhythmias. Circ Arrhythm Electrophysiol 2014;
9. Grados A, Ebbo M, Bernit E, Veit V, Mazodier K, Jean R*, et al*. Sarcoidosis Occurring After Solid Cancer: A Nonfortuitous Association: Report of 12 Cases and Review of the Literature. Medicine (Baltimore) 2015;
10. Heidelberger V, Ingen-Housz-Oro S, Marquet A, Mahevas M, Bessis D, Bouillet L*, et al*. Efficacy and Tolerance of Anti-Tumor Necrosis Factor α Agents in Cutaneous Sarcoidosis: A French Study of 46 Cases. JAMA Dermatol 2017;
11. Tseng ST, Yao TC, Huang JL, Yeh KW, Hwang YS. Clinical manifestations in uveitis patients with and without rheumatic disease in a Chinese population in Taiwan. J Microbiol Immunol Infect 2017;
12. Dhooria S, Mehta RM, Srinivasan A, Madan K, Sehgal IS, Pattabhiraman V*, et al*. The safety and efficacy of different methods for obtaining transbronchial lung cryobiopsy in diffuse lung diseases. Clin Respir J 2018;
13. Papageorgiou N, Providência R, Bronis K, Dechering DG, Srinivasan N, Eckardt L*, et al*. Catheter ablation for ventricular tachycardia in patients with cardiac sarcoidosis: a systematic review. Europace 2018;
14. Morelle G, Gueudry J, Uettwiller F, Wouters C, Bader-Meunier B, Robert MP*, et al*. Chronic and recurrent non-infectious paediatric-onset uveitis: a French cohort. RMD Open 2019;
15. Cacoub P, Chapelon-Abric C, Resche-Rigon M, Saadoun D, Desbois AC, Biard L. Cardiac sarcoidosis: A long term follow up study. PLoS One 2020;
16. Kaur D, Roukoz H, Shah M, Yalagudri S, Pandurangi U, Chennapragada S*, et al*. Impact of the inflammation on the outcomes of catheter ablation of drug-refractory ventricular tachycardia in cardiac sarcoidosis. J Cardiovasc Electrophysiol 2020;
17. Rajagopala S, Sankari S, Kancherla R, Ramanathan RP, Balalakshmoji D. Miliary Sarcoidosis: does it exist? A case series and systematic review of literature. Sarcoidosis Vasc Diffuse Lung Dis 2020;
18. Gavoille A, Desbois AC, Joubert B, Durel CA, Auvens C, Berthoux E*, et al*. Prognostic Factors and Treatment Efficacy in Spinal Cord Sarcoidosis: An Observational Cohort With Long-term Follow-up. Neurology 2022;
19. Leclercq M, Andrillon A, Maalouf G, Sève P, Bielefeld P, Gueudry J*, et al*. Anti-Tumor Necrosis Factor α versus Tocilizumab in the Treatment of Refractory Uveitic Macular Edema: A Multicenter Study from the French Uveitis Network. Ophthalmology 2022;

20. Maalouf G, Andrillon A, Leclercq M, Sève P, Bielefeld P, Gueudry J*, et al*. Lower Relapses Rate With Infliximab Versus Adalimumab in Sight-Threatening Uveitis: A Multicenter Study of 330 Patients. Am J Ophthalmol 2022;
21. Buttar C, Lakhdar S, Pavankumar T, Guzman-Perez L, Mahmood K, Collura G. Heart transplantation in end-stage heart failure secondary to cardiac sarcoidosis: an updated systematic review. Heart Fail Rev 2023;
22. Giorgiutti S, Jamilloux Y, Gerfaud-Valentin M, Bert A, Ballonzoli L, Kodjikian L*, et al*. The course of non-infectious uveitis in pregnancy: a retrospective study of 79 pregnancies. Graefes Arch Clin Exp Ophthalmol 2023;
23. Hangül M, Köse M, Pekcan S, Ersoy A, Unal G, Caglar HT. Childhood sarcoidosis in the middle Anatolia of Turkey. Pediatr Pulmonol 2023;
24. Erol S, Kaya AG, Arslan F, Oz M, Mulazimoglu DD, Isık O*, et al*. Importance of mediastinal granulomatous/sarcoid-like lymphadenopathy in extrathoracic malignancies. Diagn Cytopathol 2024;
25. Guliyeva V, Demirkan FG, Yiğit RE, Esen E, Bayındır Y, Torun R*, et al*. A clinical overview of paediatric sarcoidosis: Multicentre experience from Turkey. Mod Rheumatol 2024;
26. Damaraju V, Vutukuru S, Gandrakota G, Ravindra AG, Schramm D. A Systematic Review of Transbronchial Lung Cryobiopsy for Pediatric Interstitial Lung Diseases. Pediatr Pulmonol 2025;
27. Gomez H, Noël N, Schmidt J, Aouba A, Bourre B, Langlois V*, et al*. Comparing the efficacy and safety of cyclophosphamide, infliximab and methotrexate in neurosarcoidosis: a multicenter retrospective study. J Neurol 2025;
28. Nitsch L, Skowasch D, Courtin E, Duffau P, Otto C, Ruprecht K*, et al*. Factors Associated With Relapse in Patients With Neurosarcoidosis. Neurology 2025;
29. Shin D, Kim S, Kong M, Kim BH, Song SJ. Prevalence and Incidence of Uveitis in Korean Patients with Sarcoidosis: A Population-Based Study. Ocul Immunol Inflamm 2025;
30. Ueda A, Nakagawa K, Miyamoto K, Tonegawa-Kuji R, Igarashi M, Okubo K*, et al*. Early Corticosteroid Therapy and Its Effect on Ventricular Tachyarrhythmia Recurrence in Cardiac Sarcoidosis: A 10-Year Longitudinal Multicenter Study. J Cardiovasc Electrophysiol 2025;
31. Gibson GJ, Prescott RJ, Muers MF, Middleton WG, Mitchell DN, Connolly CK*, et al*. British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment. Thorax 1996;51(3):238–47. doi:10.1136/thx.51.3.238

Supplementary forest plots: Each forest plot displays the proportion of relapses with 95% confidence intervals (CIs) for individual studies, alongside an overall estimate using a random-effects REML model. Studies are listed with the number of relapses and total number of followed-up patients. The size of each study's square reflects its weight (%). Heterogeneity is assessed via τ^2, I^2, and H^2, with Q and p values for study differences and z and p values for the overall effect. The x-axis represents the proportion of relapses (0 to 1).



Supplementary Figure 1: Forest plot showing (a) pooled mean differences in the ages of patients with pulmonary sarcoidosis at relapse, (b) log odds ratios for the sex of patients with pulmonary sarcoidosis.



Supplementary Figure 2 (a) Excluding outliers from Baujat plot, Study numbers 34, 48, 41, 45, and 24. (b) Combination of significant outliers from Baujat and Galbraith plots study number 6, 19, and 31 have also been removed. The pooled estimates remained substantially unchanged, and heterogeneity exhibited a 5% reduction.



Supplementary Figure 3: The adult prevalence rate, with the exclusion of pediatric studies (Study numbers 2, 25, 27, 37, and 39).



(a) Prospective studies

(b) Retrospective studies

Supplementary Figure 4: Sensitivity analysis by study design, favoring prospective studies for their lower heterogeneity ($\tau^2 = 0.01$, $I^2 = 85.82\%$, $H^2 = 7.05$) and more conservative overall relapse proportion (pooled effect 0.32, 95% CI 0.26-0.38) compared to retrospective studies ($\tau^2 = 0.05$, $I^2 = 94.50\%$, $H^2 = 18.18$; pooled effect 0.45, 95% CI 0.36-0.54). (a) Prospective studies. (b) Retrospective studies.



Supplementary Figure 5: Sensitivity analysis for the effect of definition (a) Studies with relapse definition (b) Studies without relapse definition



Supplementary Figure 6: Sensitivity analysis for quality (a) Studies with low risk of bias (b) Studies without moderate risk of bias



Supplementary Figure 7: Sensitivity analysis to assess small-study effects. (a) Studies with ≥50 patients followed up. (b) Studies with < 50 patients followed



Supplementary Figure 8: Effect of Geographical area (a) Studies form Asian countries and (b) Studies form non-Asian countries



Supplementary Figure 9: Effect of year of publication (a) Studies after 2000 CE and (b) before 2000 CE



Supplementary Figure 10: Leave-one-out analysis by sequentially excluding each study and recalculating the pooled prevalence